Postpartum Depression

Psychiatric MONDO:0005929 Pathograph 10 Show in embeddings browser depressive disorder puerperal disorder

Postpartum depression (PPD) is a major depressive episode with onset during pregnancy or in the weeks to months following delivery. It is the most common medical complication of childbirth, affecting roughly one in eight women in high-income settings and substantially more in low- and middle-income countries, and it carries consequences for the mother, the mother-infant relationship, and infant cognitive and behavioral development. PPD is distinguished from other major depressive episodes by a reproductive-endocrine trigger: the supraphysiologic gonadal steroid levels of late pregnancy fall precipitously at parturition, and in a susceptible subgroup of women this withdrawal of progesterone-derived neurosteroids — chiefly allopregnanolone, a positive allosteric modulator of GABA-A receptors — precipitates depression. This mechanism is unusually well validated for a psychiatric disorder, because it has been tested experimentally by hormone withdrawal in humans, modeled genetically in mice, and exploited therapeutically: brexanolone and zuranolone, both neuroactive-steroid GABA-A positive allosteric modulators, were developed directly from it. Zuranolone, taken orally for 14 days, is the surviving mechanism-matched treatment; brexanolone, the intravenous forerunner that proved the principle, was withdrawn from the market in April 2025 for commercial rather than efficacy reasons. Hypothalamic-pituitary-adrenal axis dysregulation, inflammatory signaling, and heritable differences in estrogen-driven epigenetic reprogramming contribute additional risk.

Ask OpenScientist

Ask a research question about Postpartum Depression. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

8
Pathophys.
8
Phenotypes
2
Hypotheses
3
Gaps
10
Pathograph
4
Genes
4
Medical Actions
3
Trials
1
Deep Research
🏷

Classifications

Harrison's Part
NEUROLOGIC
◈

Mechanistic Hypotheses

2
Neurosteroid (allopregnanolone) withdrawal and GABA-A receptor plasticity failure
neurosteroid_withdrawal_model CANONICAL
Evidence balance 2 support
The dominant model holds that PPD is triggered by the precipitous fall in progesterone-derived neurosteroids at parturition, acting on GABA-A receptors whose subunit composition has been remodeled across pregnancy. Women who fail to re-adapt receptor stoichiometry to the new neurosteroid milieu experience a loss of inhibitory tone and depressive symptoms. The model is supported by an experimental human hormone-withdrawal paradigm, by a genetic mouse model of failed GABA-A delta-subunit regulation, and — most persuasively — by the efficacy of two neuroactive-steroid GABA-A positive allosteric modulators developed directly from it.
Pathograph links
Gestational Neurosteroid Surge -> Precipitous Postpartum Neurosteroid Withdrawal DIRECT Delivery of the placenta removes the source that sustained the surge, converting the rising limb into the steepest neurosteroid fall in normal human physiology.
Gestational Neurosteroid Surge -> Failure of GABA-A Receptor Subunit Plasticity DIRECT Sustained high neurosteroid exposure across gestation is the stimulus that drives homeostatic remodeling of GABA-A receptor subunit composition.
Precipitous Postpartum Neurosteroid Withdrawal -> Failure of GABA-A Receptor Subunit Plasticity DIRECT The fall in neurosteroid is what exposes any failure to re-adapt receptor stoichiometry: a receptor population tuned to the gestational milieu becomes mismatched the moment that milieu disappears.
Failure of GABA-A Receptor Subunit Plasticity -> Loss of GABAergic Inhibitory Tone DIRECT Mismatched receptor subunit composition leaves inhibitory signaling inadequate for the abruptly neurosteroid-depleted postpartum brain.
Loss of GABAergic Inhibitory Tone -> Postpartum Major Depressive Episode INDIRECT KNOWN INTERMEDIATES Reduced inhibitory control in mood-regulating circuits manifests as the depressive syndrome; restoring GABA-A modulation reverses it within days. Intermediates: Limbic and corticolimbic circuit dysfunction consequent to reduced inhibitory tone.
Show evidence (2 references)
PMID:10831472 SUPPORT Human Clinical
"The data provide direct evidence in support of the involvement of the reproductive hormones estrogen and progesterone in the development of postpartum depression in a subgroup of women"
Experimental simulation of pregnancy-level steroids followed by blinded withdrawal provides the direct human causal test underpinning the withdrawal model.
PMID:28619476 SUPPORT Human Clinical
"Post-partum depression is a serious mood disorder in women that might be triggered by peripartum fluctuations in reproductive hormones."
States the hormonal-fluctuation trigger hypothesis that motivated allopregnanolone replacement as a therapeutic strategy.
Placental CRH-driven HPA axis dysregulation
hpa_axis_crh_model ALTERNATIVE
Evidence balance 1 support
A complementary model attributes PPD risk to dysregulation of the hypothalamic-pituitary-adrenal axis. Placental corticotropin-releasing hormone rises exponentially across gestation and suppresses hypothalamic CRH; its abrupt withdrawal after delivery leaves a transiently hyporesponsive axis. Accelerated mid-gestation pCRH trajectories predict postpartum depressive symptoms independently of prenatal mood, and notably without parallel cortisol or ACTH signals, suggesting a placental rather than adrenal locus.
Pathograph links
Placental CRH Elevation -> Postpartum HPA Axis Hyporesponsiveness DIRECT Sustained placental CRH suppresses maternal hypothalamic CRH output; its abrupt removal at delivery leaves the axis transiently unable to respond.
Postpartum HPA Axis Hyporesponsiveness -> Postpartum Major Depressive Episode INDIRECT UNKNOWN INTERMEDIATES The intermediates linking an accelerated pCRH trajectory to depressive symptom onset are not established in humans; the association is predictive rather than mechanistically resolved.
Show evidence (1 reference)
PMID:19188538 SUPPORT Human Clinical
"Growth curve analyses indicated that the trajectories of pCRH in women with PPD symptoms are significantly accelerated from 23 to 26 weeks' GA."
Longitudinal cohort evidence that a placental CRH trajectory, not a cortisol/ACTH signal, marks women who develop postpartum depressive symptoms.
?

Discussions and Knowledge Gaps

3
If PPD is caused by perinatal reproductive hormone change, why do many studies fail to find any difference in hormone concentrations between women who develop PPD and those who do not?
CONTROVERSY OPEN ppd_hormone_concentration_null_findings
Attached to
pathophysiology#Precipitous Postpartum Neurosteroid Withdrawal
The withdrawal model is not a claim about hormone levels but about differential sensitivity to a hormone change that all postpartum women experience. Correlational studies comparing absolute concentrations are therefore underpowered to detect the mechanism by construction, and their null results have repeatedly been misread as refuting the model. Resolving this requires sensitivity-stratified rather than concentration-stratified designs — the logic of the experimental withdrawal paradigm and of the estrogen-responsive methylation biomarker work.
Show evidence (2 references)
PMID:25263255 SUPPORT Human Clinical
"Although a number of human and nonhuman animal studies support the role of reproductive hormones in PPD, several studies have failed to detect an association between hormone concentrations and PPD."
States the discrepancy directly: mechanistic support coexists with null concentration-association findings.
PMID:25263255 SUPPORT Human Clinical
"Reproductive hormones influence virtually every biological system implicated in PPD, and a subgroup of women seem to be particularly sensitive to the effects of perinatal changes in hormone levels."
Articulates the hormone-sensitive-subgroup resolution that reconciles the positive mechanistic and null correlational literatures.
Does the Gabrd mouse model's failed GABA-A delta-subunit plasticity correspond to a demonstrable receptor-remodeling defect in women with postpartum depression?
HUMAN MODEL MISMATCH OPEN ppd_gabrd_mouse_translation
Attached to
pathophysiology#Failure of GABA-A Receptor Subunit Plasticity
The subunit-plasticity step is the mechanistic core of the canonical model, yet the direct evidence for it is entirely murine: delta and gamma2 downregulation across pregnancy with postpartum rebound, and a depression-like phenotype in Gabrd heterozygotes and nulls. Human support is indirect, inferred from the therapeutic efficacy of GABA-A positive allosteric modulators, which would also be expected if the receptor population were normal and only the ligand were withdrawn. Distinguishing failed receptor plasticity from simple ligand withdrawal matters because it determines whether PPD susceptibility is a receptor trait or a steroid-metabolism trait, and hence whether prophylaxis should target receptor adaptation or neurosteroid maintenance.
Proposed experiments
Human GABA-A delta/gamma2 subunit trajectory across pregnancy and postpartum
exp_ppd_human_gabaa_subunit_trajectory
Quantify GABA-A delta- and gamma2-subunit expression or availability across late pregnancy and the early postpartum in women with and without postpartum depression, using PET ligands sensitive to receptor subtype availability and, where obtainable, postmortem or biopsy tissue. The mouse model predicts downregulation across pregnancy with immediate postpartum rebound; failure of that rebound in affected women would establish the plasticity step in humans.
GABRD variant stratification of neuroactive-steroid treatment response
exp_ppd_gabrd_variant_treatment_response
Test whether GABRD variants stratify response to brexanolone or zuranolone in the completed phase 2/3 trial cohorts. If failed delta-subunit plasticity is the human lesion, GABRD genotype should modify the magnitude of response to delta-subunit-active neuroactive steroids; if the lesion is purely ligand withdrawal, it should not.
Show evidence (1 reference)
PMID:18667149 SUPPORT Model Organism
"We suggest that Gabrd(+/-) and Gabrd(-/-) mice constitute a mouse model of postpartum depression that may be useful for evaluating potential therapeutic interventions."
The authors present the plasticity-failure evidence explicitly as a mouse model, leaving human correspondence to be established.
Postpartum depression risk shares a genome-wide significant locus with premenstrual disorder at KCTD16, an auxiliary subunit of the metabotropic GABA-B receptor, yet every mechanistic and therapeutic strand in this entry runs through the ionotropic GABA-A receptor. Does GABA-B signalling contribute to the loss of inhibitory tone in postpartum depression, or is the KCTD16 association acting through something other than the receptor complex its protein belongs to?
KNOWLEDGE GAP OPEN ppd_gabab_versus_gabaa_inhibitory_axis
Attached to
pathophysiology#Loss of GABAergic Inhibitory Tone genetic#KCTD16
The two claims are not in conflict, but nothing currently connects them. The curated chain is neurosteroid withdrawal acting on GABA-A receptors, and it is supported by the efficacy of two GABA-A positive allosteric modulators. Allopregnanolone has no comparable action at GABA-B receptors, so a genuine GABA-B contribution would have to be a parallel route to reduced inhibitory tone rather than a step in the neurosteroid pathway. Resolving this matters for two reasons. First, it determines whether the shared premenstrual-disorder and postpartum-depression liability is hormone-response machinery or general inhibitory tone, which is what makes the two disorders cross-inherited. Second, it is the difference between a treatment landscape confined to neuroactive steroids and one that includes GABA-B-directed agents. The evidence is currently thin on both sides: the locus is a single unreplicated preprint finding whose functional consequence for KCTD16 expression is unmeasured, and the KCTD16 to GABA-B link, while solid, comes from rodent brain proteomics with no postpartum context.
Proposed experiments
Replication of the KCTD16 shared locus and its effect on KCTD16 expression
exp_ppd_kctd16_replication_and_expression
Replicate the cross-trait premenstrual-disorder and postpartum-depression association at the KCTD16 3' UTR locus in an independent, ideally non-European-ancestry cohort, and determine the direction of effect on hippocampal KCTD16 expression. A peer-reviewed replication with a measured expression direction is the precondition for treating GABA-B signalling as a mechanism here rather than as an unexplained association.
GABA-B contribution to inhibitory tone in a neurosteroid-withdrawal model
exp_ppd_gabab_tone_in_withdrawal_model
In the pseudopregnancy or Gabrd model, test whether GABA-B receptor signalling changes across the peripartum transition independently of GABA-A subunit remodeling, and whether manipulating Kctd16 alters the postpartum depression-like phenotype. A phenotype that moves with Kctd16 but not with GABA-A subunit composition would establish GABA-B as a parallel route to loss of inhibitory tone; no effect would argue the human locus acts elsewhere.
Show evidence (3 references)
PPR:PPR1293935 Preprint · not peer-reviewed SUPPORT Human Clinical
"locus implicates GABAB–mediated inhibitory signaling in both disorders"
States the GABA-B interpretation that this entry's GABA-A-centred mechanism does not currently accommodate.
PPR:PPR1293935 Preprint · not peer-reviewed SUPPORT Human Clinical
"The register-based heritability was 0.35 (95% CI: 0.29–0.41) for PMD and 0.31 (95% CI: 0.23–0.37) for PPD, with a positive genetic correlation between these disorders"
Quantifies the shared heritable liability that the KCTD16 and PCDH9 loci are proposed to partly explain, establishing that there is a real cross-disorder signal to account for.
PPR:PPR1293935 Preprint · not peer-reviewed SUPPORT Human Clinical
"Beyond the lead loci, TWAS suggested that the shared risk variants may partially act through genetically regulated gene expression across brain, endocrine and immune-related tissues"
The authors themselves treat the mechanistic route as unsettled and distributed beyond the lead loci, which is why this is recorded as an open gap rather than as a curated mechanism.
⚙

Pathophysiology

8
Gestational Neurosteroid Surge
Across pregnancy, placental and ovarian steroidogenesis raises circulating progesterone and its 5-alpha-reduced neurosteroid metabolite allopregnanolone to supraphysiologic levels. This is the rising limb, and it is a normal feature of every pregnancy — it is pathogenic only as the setup for the fall that follows, by remodeling GABA-A receptors to a high-neurosteroid environment that will not persist.
Neurosteroid (allopregnanolone) withdrawal and GABA-A receptor plasticity failure
steroid biosynthetic process GO:0006694 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased steroid biosynthetic process (GO:0006694). GO:0006694 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Precipitous Postpartum Neurosteroid Withdrawal Delivery of the placenta removes the source that sustained the surge, converting the rising limb into the steepest neurosteroid fall in normal human physiology. Neurosteroid (allopregnanolone) withdrawal and GABA-A receptor plasticity failure
Failure of GABA-A Receptor Subunit Plasticity Sustained high neurosteroid exposure across gestation is the stimulus that drives homeostatic remodeling of GABA-A receptor subunit composition. Neurosteroid (allopregnanolone) withdrawal and GABA-A receptor plasticity failure
Show evidence (1 reference)
PMID:18667149 SUPPORT Model Organism
"The large increase in progesterone-derived neurosteroids during pregnancy and their precipitous decline at parturition may have considerable effects on GABA(A)Rs during pregnancy and postpartum."
Establishes the gestational rise in progesterone-derived neurosteroids as the first limb of the surge-and-withdrawal cycle.
Precipitous Postpartum Neurosteroid Withdrawal
Delivery of the placenta removes the dominant source of progesterone-derived neurosteroid within hours, producing the steepest neurosteroid withdrawal in normal human physiology. The withdrawal itself is universal; what distinguishes women who develop PPD is differential sensitivity to it, established experimentally by inducing and then withdrawing pregnancy-level estradiol and progesterone under double-blind conditions.
Neurosteroid (allopregnanolone) withdrawal and GABA-A receptor plasticity failure
steroid biosynthetic process GO:0006694 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased steroid biosynthetic process (GO:0006694). GO:0006694 is a biological process from the Gene Ontology. ↓ DECREASED response to progesterone GO:0032570 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal response to progesterone (GO:0032570). GO:0032570 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Failure of GABA-A Receptor Subunit Plasticity The fall in neurosteroid is what exposes any failure to re-adapt receptor stoichiometry: a receptor population tuned to the gestational milieu becomes mismatched the moment that milieu disappears. Neurosteroid (allopregnanolone) withdrawal and GABA-A receptor plasticity failure
Estrogen-Sensitive Epigenetic Reprogramming in Susceptible Women The same perinatal steroid excursion drives estrogen-responsive epigenetic reprogramming, which appears altered in women who go on to develop PPD.
Show evidence (2 references)
PMID:10831472 SUPPORT Human Clinical
"Five of the eight women with a history of postpartum depression (62.5%) and none of the eight women in the comparison group developed significant mood symptoms during the withdrawal period."
Blinded withdrawal of simulated pregnancy-level steroids reproduced mood symptoms only in women with a PPD history, isolating steroid withdrawal as the proximate trigger.
PMID:10831472 SUPPORT Human Clinical
"they suggest that women with a history of postpartum depression are differentially sensitive to mood-destabilizing effects of gonadal steroids"
Establishes differential steroid sensitivity, rather than an abnormal hormone concentration, as the susceptibility trait.
Failure of GABA-A Receptor Subunit Plasticity
GABA-A receptors normally adapt to the pregnancy neurosteroid environment by downregulating delta and gamma2 subunits, then rebounding immediately postpartum as neurosteroid levels fall. Delta-subunit-containing extrasynaptic receptors mediate tonic inhibition and are the principal neurosteroid-sensitive population, while gamma2-containing synaptic receptors mediate phasic inhibition. Mice genetically unable to perform the delta-subunit adaptation develop depression-like and abnormal maternal behavior, identifying failed receptor plasticity — rather than the hormone change itself — as the pathogenic step.
Neurosteroid (allopregnanolone) withdrawal and GABA-A receptor plasticity failure
GABAergic neuron CL:0000617 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves GABAergic neuron (CL:0000617). CL:0000617 is a cell type from the Cell Ontology. hippocampal neuron CL:0002608 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hippocampal neuron (CL:0002608). CL:0002608 is a cell type from the Cell Ontology.
regulation of postsynaptic membrane neurotransmitter receptor levels GO:0099072 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal regulation of postsynaptic membrane neurotransmitter receptor levels (GO:0099072). GO:0099072 is a biological process from the Gene Ontology. ⚠ ABNORMAL gamma-aminobutyric acid signaling pathway GO:0007214 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased gamma-aminobutyric acid signaling pathway (GO:0007214). GO:0007214 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Loss of GABAergic Inhibitory Tone Mismatched receptor subunit composition leaves inhibitory signaling inadequate for the abruptly neurosteroid-depleted postpartum brain. Neurosteroid (allopregnanolone) withdrawal and GABA-A receptor plasticity failure
Show evidence (2 references)
PMID:18667149 SUPPORT Model Organism
"Here we show a significant decrease in tonic and phasic inhibitions in pregnant mice, mediated by a downregulation of GABA(A)R delta and gamma2 subunits, respectively, which rebounds immediately postpartum."
Demonstrates the physiological receptor-remodeling program across pregnancy and its postpartum rebound in a mouse model.
PMID:18667149 SUPPORT Model Organism
"Mice which do not exhibit GABA(A)R delta subunit regulation throughout pregnancy (Gabrd(+/-) and Gabrd(-/-)) exhibit depression-like and abnormal maternal behaviors, resulting in reduced pup survival."
Genetic loss of delta-subunit plasticity is sufficient to produce a PPD-like behavioral phenotype, supporting causality of the plasticity failure.
Loss of GABAergic Inhibitory Tone
The net consequence of neurosteroid withdrawal against a maladapted receptor population is reduced tonic and phasic GABAergic inhibition in limbic circuits regulating mood and maternal behavior. This node is the convergent target of both approved mechanism-matched drugs, which restore positive allosteric modulation at synaptic and extrasynaptic GABA-A receptors. Its therapeutic reversibility is the strongest evidence that the node is causal rather than correlative.
Neurosteroid (allopregnanolone) withdrawal and GABA-A receptor plasticity failure
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology. GABAergic neuron CL:0000617 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves GABAergic neuron (CL:0000617). CL:0000617 is a cell type from the Cell Ontology.
inhibitory postsynaptic potential GO:0060080 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased inhibitory postsynaptic potential (GO:0060080). GO:0060080 is a biological process from the Gene Ontology. ↓ DECREASED gamma-aminobutyric acid signaling pathway GO:0007214 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased gamma-aminobutyric acid signaling pathway (GO:0007214). GO:0007214 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Postpartum Major Depressive Episode Reduced inhibitory control in mood-regulating circuits manifests as the depressive syndrome; restoring GABA-A modulation reverses it within days. Neurosteroid (allopregnanolone) withdrawal and GABA-A receptor plasticity failure
Show evidence (2 references)
PMID:18667149 SUPPORT Model Organism
"These abnormal postpartum behaviors were ameliorated in Gabrd(+/-) mice by a GABA(A)R delta-subunit-selective agonist, THIP."
Pharmacological restoration of delta-subunit-mediated tonic inhibition rescues the PPD-like phenotype, establishing loss of inhibitory tone as the proximate and reversible lesion.
PMID:30177236 SUPPORT Human Clinical
"We assessed brexanolone injection (formerly SAGE-547 injection), a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors, for the treatment of moderate to severe post-partum depression."
Human phase 3 program built on restoring GABA-A positive allosteric modulation, translating the inhibitory-tone node into therapy.
Placental CRH Elevation
The placenta secretes corticotropin-releasing hormone in exponentially rising quantities across gestation. Unlike hypothalamic CRH, placental CRH is upregulated rather than suppressed by cortisol, creating a feed-forward loop. Women whose mid-gestation pCRH rises fastest are at elevated risk of postpartum depressive symptoms — an association that holds after adjusting for prenatal depressive symptoms.
Placental CRH-driven HPA axis dysregulation
cellular response to corticotropin-releasing hormone stimulus GO:0071376 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased cellular response to corticotropin-releasing hormone stimulus (GO:0071376). GO:0071376 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Postpartum HPA Axis Hyporesponsiveness Sustained placental CRH suppresses maternal hypothalamic CRH output; its abrupt removal at delivery leaves the axis transiently unable to respond. Placental CRH-driven HPA axis dysregulation
Show evidence (2 references)
PMID:19188538 SUPPORT Human Clinical
"Growth curve analyses indicated that the trajectories of pCRH in women with PPD symptoms are significantly accelerated from 23 to 26 weeks' GA."
Identifies an accelerated mid-gestation pCRH trajectory, rather than a single elevated value, as the risk-marking feature.
PMID:19188538 SUPPORT Human Clinical
"At 25 weeks' GA, pCRH was a strong predictor of PPD symptoms"
Prospective cohort finding that mid-gestation placental CRH predicts postpartum depressive symptoms.
Postpartum HPA Axis Hyporesponsiveness
Placental delivery abruptly removes the dominant CRH source, leaving a transiently hyporesponsive hypothalamic-pituitary-adrenal axis while suppressed hypothalamic CRH output recovers. Notably the risk signal in human data attaches to placental CRH and is not mirrored by cortisol or ACTH, which constrains this arm to a placental rather than adrenal locus.
Placental CRH-driven HPA axis dysregulation
cellular response to corticotropin-releasing hormone stimulus GO:0071376 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated cellular response to corticotropin-releasing hormone stimulus (GO:0071376). GO:0071376 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Downstream
Postpartum Major Depressive Episode The intermediates linking an accelerated pCRH trajectory to depressive symptom onset are not established in humans; the association is predictive rather than mechanistically resolved. Placental CRH-driven HPA axis dysregulation
Show evidence (1 reference)
PMID:19188538 SUPPORT Human Clinical
"No significant associations were found for cortisol and ACTH."
Constrains the mechanism to a placental CRH signal rather than generalized adrenal HPA overactivity, and limits how far the HPA model can be extended.
Estrogen-Sensitive Epigenetic Reprogramming in Susceptible Women
Susceptibility to PPD appears to reside partly in how a woman's genome responds epigenetically to the perinatal estrogen excursion, rather than in the size of the excursion itself. Antenatal blood DNA methylation at estrogen-responsive loci — identified by cross-referencing human prospective profiles with hippocampal methylation changes induced by 17-beta-estradiol in mice — discriminates women who will develop PPD, with HP1BP3 and TTC9B as the two replicated biomarker loci. This provides a molecular correlate for the differential steroid sensitivity demonstrated experimentally.
hippocampal neuron CL:0002608 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hippocampal neuron (CL:0002608). CL:0002608 is a cell type from the Cell Ontology.
cellular response to estrogen stimulus GO:0071391 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal cellular response to estrogen stimulus (GO:0071391). GO:0071391 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Downstream
Postpartum Major Depressive Episode Epigenetic sensitivity is a susceptibility modifier; the pathway from methylation state to symptom onset is not resolved.
Show evidence (2 references)
PMID:23689534 SUPPORT Human Clinical
"DNA methylation associated with PPD risk correlated significantly with E2-induced DNA methylation change, suggesting an enhanced sensitivity to estrogen-based DNA methylation reprogramming exists in those at risk for PPD"
Cross-species design linking altered estrogen-driven epigenetic reprogramming to PPD risk, giving a molecular basis for differential hormone sensitivity.
PMID:23689534 SUPPORT Human Clinical
"we identified two biomarker loci at the HP1BP3 and TTC9B genes that predicted PPD with an area under the receiver operator characteristic (ROC) curve (area under the curve (AUC)) of 0.87 in antenatally euthymic women"
Identifies the specific replicated loci and quantifies antenatal predictive performance in euthymic women.
Postpartum Major Depressive Episode
The convergent clinical endpoint: a major depressive episode with peripartum onset, comprising depressed mood, anhedonia, sleep and appetite disturbance, impaired concentration, anxiety, and in severe cases suicidal ideation. Beyond the mother, the episode disrupts maternal-infant bonding and is associated with adverse infant cognitive and behavioral outcomes. Rapid reversibility with neuroactive-steroid therapy — meaningful separation from placebo by day 3 — distinguishes the syndrome pharmacodynamically from non-puerperal major depression treated with monoaminergic agents.
gamma-aminobutyric acid signaling pathway GO:0007214 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased gamma-aminobutyric acid signaling pathway (GO:0007214). GO:0007214 is a biological process from the Gene Ontology. ↓ DECREASED
Show evidence (2 references)
PMID:34190962 SUPPORT Human Clinical
"Postpartum depression (PPD) is one of the most common medical complications during and after pregnancy, negatively affecting both mother and child."
Frames the clinical endpoint and its two-generation impact.
PMID:34190962 SUPPORT Human Clinical
"Sustained differences in HAMD-17 scores favoring zuranolone were observed from day 3"
Documents onset of benefit by day 3, the rapid pharmacodynamic signature of neurosteroid replacement in this syndrome.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Postpartum Depression Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

8
Digestive 1
Poor appetite HP:0004396 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Poor appetite (HP:0004396). HP:0004396 is a phenotype from the Human Phenotype Ontology.
Nervous System 6
Depressed mood Depression HP:0000716 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Depression (HP:0000716). HP:0000716 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37491938 SUPPORT Human Clinical
"Postpartum depression (PPD) is a common perinatal complication with adverse maternal and infant outcomes."
Confirms the depressive syndrome as the defining clinical presentation of the disorder.
Anhedonia HP:0012154 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anhedonia (HP:0012154). HP:0012154 is a phenotype from the Human Phenotype Ontology.
Anxiety HP:0000739 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anxiety (HP:0000739). HP:0000739 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:34190962 SUPPORT Human Clinical
"Hamilton Rating Scale for Anxiety score (difference, -3.9; 95% CI, -6.7 to -1.1; P = .006)"
Anxiety was a prespecified secondary endpoint that improved with treatment, documenting it as a component of the PPD phenotype.
Insomnia HP:0100785 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Insomnia (HP:0100785). HP:0100785 is a phenotype from the Human Phenotype Ontology.
Irritability HP:0000737 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Irritability (HP:0000737). HP:0000737 is a phenotype from the Human Phenotype Ontology.
Suicidal ideation HP:0031589 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Suicidal ideation (HP:0031589). HP:0031589 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:37491938 SUPPORT Human Clinical
"No loss of consciousness, withdrawal symptoms, or increased suicidal ideation or behavior were observed."
Suicidal ideation was tracked as a safety endpoint in severe PPD, reflecting its clinical relevance in this population.
Constitutional 1
Fatigue HP:0012378 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Fatigue (HP:0012378). HP:0012378 is a phenotype from the Human Phenotype Ontology.
🧬

Genetic Associations

4
HP1BP3 (Antenatal blood DNA methylation at HP1BP3, an estrogen-responsive locus identified by cross-referencing human prospective methylation profiles with estradiol-induced hippocampal methylation changes in mice, is one of two replicated biomarker loci predicting subsequent PPD.)
Gene: HP1BP3 hgnc:24973 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is HP1BP3 (hgnc:24973). hgnc:24973 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: BIOMARKER
Show evidence (1 reference)
PMID:23689534 SUPPORT Human Clinical
"we identified two biomarker loci at the HP1BP3 and TTC9B genes that predicted PPD with an area under the receiver operator characteristic (ROC) curve (area under the curve (AUC)) of 0.87 in antenatally euthymic women"
Identifies HP1BP3 methylation as an antenatal predictive biomarker locus for PPD.
TTC9B (TTC9B is the second replicated estrogen-responsive methylation biomarker locus; combined with HP1BP3 and blood count data the model predicted PPD across both antenatally euthymic and antenatally depressed women.)
Gene: TTC9B hgnc:26395 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TTC9B (hgnc:26395). hgnc:26395 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: BIOMARKER
Show evidence (1 reference)
PMID:23689534 SUPPORT Human Clinical
"Incorporation of blood count data into the model accounted for the discrepancy and produced an AUC of 0.96 across both prepartum depressed and euthymic women."
Quantifies combined-model performance for the two-locus methylation biomarker after adjustment for blood cell composition.
KCTD16 (A cross-trait GWAS meta-analysis of premenstrual disorder and postpartum depression identified a shared genome-wide significant locus in the 3' untranslated region of KCTD16. KCTD16 encodes one of the KCTD auxiliary subunits that assemble onto the GABA-B2 subunit and set the agonist potency and signalling kinetics of the native GABA-B receptor, so the locus implicates metabotropic GABA-B inhibitory signalling in postpartum depression. This is a different inhibitory axis from the ionotropic GABA-A neurosteroid mechanism the rest of this entry models. Transcriptome-wide association localised the regulatory signal to hippocampus, with no comparable signal in other brain regions or peripheral tissues.)
Gene: KCTD16 hgnc:29244 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is KCTD16 (hgnc:29244). hgnc:29244 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (5 references)
PPR:PPR1293935 Preprint · not peer-reviewed SUPPORT Human Clinical
"Cross-trait meta-analysis identified two novel genome-wide significant loci jointly associated with PMD and PPD"
Establishes KCTD16 as one of the two loci reaching genome-wide significance in the joint premenstrual-disorder and postpartum-depression analysis.
PPR:PPR1293935 Preprint · not peer-reviewed SUPPORT Human Clinical
"locus implicates GABAB–mediated inhibitory signaling in both disorders"
The authors' own reading of the KCTD16 signal, naming GABA-B rather than GABA-A as the implicated inhibitory pathway.
PPR:PPR1293935 Preprint · not peer-reviewed SUPPORT Human Clinical
"with no detectable trend effects in other brain regions or peripheral tissues"
Tissue specificity of the KCTD16 transcriptome-wide signal: hippocampus only, which is the region where the neurosteroid-sensitive GABAergic mechanism of this entry is also localised.
+ 2 more references
PCDH9 (The second genome-wide significant locus shared between premenstrual disorder and postpartum depression in the same cross-trait meta-analysis maps to an intronic region of PCDH9, a non-clustered protocadherin. No mechanism linking this locus to peripartum mood regulation has been established, and the preprint offers none beyond the association itself.)
Gene: PCDH9 hgnc:8661 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is PCDH9 (hgnc:8661). hgnc:8661 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (1 reference)
PPR:PPR1293935 Preprint · not peer-reviewed SUPPORT Human Clinical
"Cross-trait meta-analysis identified two novel genome-wide significant loci jointly associated with PMD and PPD"
Establishes PCDH9 as the second of the two shared genome-wide significant loci; the mechanistic interpretation is left open by the authors.
💊

Medical Actions

4
Brexanolone
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: brexanolone CHEBI:50169 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses brexanolone (CHEBI:50169). CHEBI:50169 is a therapeutic agent from Chemical Entities of Biological Interest.
Brexanolone is an intravenous formulation of allopregnanolone, the progesterone-derived neurosteroid whose postpartum withdrawal is the proposed trigger of PPD. Administered as a single 60-hour continuous infusion, it acts as a positive allosteric modulator of synaptic and extrasynaptic GABA-A receptors, directly replacing the withdrawn endogenous modulator. It was the first drug approved specifically for postpartum depression (FDA 2019) and remains the archetypal mechanism-matched therapy in this entry — the trial evidence below is what established the neurosteroid-replacement principle that zuranolone now delivers orally. WITHDRAWN FROM MARKET: brexanolone is no longer commercially available. Sage Therapeutics notified FDA that the product was no longer marketed and requested withdrawal; FDA withdrew approval of NDA 211371 as of 2025-04-14. The 60-hour monitored intravenous infusion, the REMS requirement arising from a boxed warning for excessive sedation and sudden loss of consciousness, and the drug's cost are the widely cited practical reasons the product did not survive commercially. It is retained in this entry because its trial data remain the primary human evidence for the causal role of the inhibitory-tone node, not because it is a current treatment option.
Mechanism Target:
RESTORES Loss of GABAergic Inhibitory Tone — Intravenous allopregnanolone restores positive allosteric modulation at synaptic and extrasynaptic GABA-A receptors, replacing the neurosteroid tone lost at parturition.
Show evidence (4 references)
PMID:28619476 SUPPORT Human Clinical
"At 60 h, mean reduction in HAM-D total score from baseline was 21·0 points (SE 2·9) in the brexanolone group compared with 8·8 points (SE 2·8) in the placebo group"
Phase 2 randomised placebo-controlled trial establishing efficacy of allopregnanolone replacement in severe PPD.
PMID:30177236 SUPPORT Human Clinical
"In study 1, at 60 h, the least-squares (LS) mean reduction in HAM-D total score from baseline was 19·5 points (SE 1·2) in the BRX60 group and 17·7 points (1·2) in the BRX90 group compared with 14·0 points (1·1) in the placebo group"
Two phase 3 trials confirming benefit over placebo across moderate and severe PPD, supporting the mechanism-matched treatment rationale.
url:https://www.govinfo.gov/content/pkg/FR-2025-03-14/html/2025-04101.htm SUPPORT Other
"Therefore, approval of NDA 211371, and all amendments and supplements thereto, is hereby withdrawn as of April 14, 2025."
Federal Register notice (FDA, Docket FDA-2024-N-5852) recording formal withdrawal of brexanolone's marketing approval. Regulatory status, not a study result, hence evidence_source OTHER.
+ 1 more reference
Zuranolone
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: zuranolone CHEBI:228302 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses zuranolone (CHEBI:228302). CHEBI:228302 is a therapeutic agent from Chemical Entities of Biological Interest.
Zuranolone is an orally bioavailable neuroactive steroid and positive allosteric modulator of synaptic and extrasynaptic GABA-A receptors, given as a once-daily 14-day course. It applies the same neurosteroid-replacement logic as brexanolone without requiring a 60-hour monitored intravenous infusion, and separates from placebo by day 3.
Mechanism Target:
RESTORES Loss of GABAergic Inhibitory Tone — Oral neuroactive steroid restoring positive allosteric modulation at synaptic and extrasynaptic GABA-A receptors.
Show evidence (2 references)
PMID:37491938 SUPPORT Human Clinical
"Treatment with zuranolone compared with placebo resulted in statistically significant improvement in depressive symptoms at day 15"
Phase 3 SKYLARK trial of zuranolone 50 mg in severe PPD demonstrating efficacy on the primary endpoint.
PMID:34190962 SUPPORT Human Clinical
"Zuranolone demonstrated significant day 15 HAMD-17 score improvements from baseline vs placebo (-17.8 vs -13.6; difference, -4.2; 95% CI, -6.9 to -1.5; P = .003)."
Earlier phase 3 trial of zuranolone 30 mg confirming benefit on the primary HAMD-17 endpoint.
Selective serotonin reuptake inhibitor therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: sertraline CHEBI:9123 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses sertraline (CHEBI:9123). CHEBI:9123 is a therapeutic agent from Chemical Entities of Biological Interest.
SSRIs such as sertraline remain a mainstay of PPD pharmacotherapy, particularly outside the acute severe presentations studied in the neuroactive-steroid trials. They act on monoaminergic rather than neurosteroid-GABAergic mechanisms and have a slower onset, and are therefore not linked to a pathophysiology node in this entry.
Psychotherapy
Action: PsychotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Psychotherapy (NCIT:C15308). NCIT:C15308 is a clinical intervention from the NCI Thesaurus. NCIT:C15308
Structured psychotherapies, principally cognitive behavioral therapy and interpersonal psychotherapy, are first-line for mild to moderate PPD and are used alongside pharmacotherapy in severe disease.
🌍

Environmental Factors

2
Prior history of postpartum depression
A previous postpartum depressive episode is among the strongest predictors of recurrence and identifies the hormone-sensitive subgroup that responds to experimental steroid withdrawal with mood symptoms.
Show evidence (1 reference)
PMID:10831472 SUPPORT Human Clinical
"Five of the eight women with a history of postpartum depression (62.5%) and none of the eight women in the comparison group developed significant mood symptoms during the withdrawal period."
Prior PPD history marks differential steroid sensitivity, which is the trait conferring risk on re-exposure.
Low- and middle-income country setting
Perinatal depression prevalence is significantly higher in low- and middle-income countries than in high-income countries, reflecting socioeconomic stressors, reduced social support, and limited access to perinatal mental health services.
Show evidence (1 reference)
PMID:28531848 SUPPORT Human Clinical
"prevalence was significantly higher in women from low and middle income countries compared to women from high income countries (OR 1.8, 95% CI 1.4-2.2)"
Meta-regression quantifying the income-setting gradient in perinatal depression prevalence.
🔬

Diagnosis

1
Perinatal depression screening
PPD is diagnosed clinically against DSM-5 major depressive episode criteria with the peripartum-onset specifier; there is no PPD-specific diagnostic algorithm. Case detection therefore rests on screening instruments — the Edinburgh Postnatal Depression Scale, a 10-item perinatal-specific self-report measure that also captures anxiety items, and the PHQ-9, both validated in this population. Screening policy diverges internationally: US bodies recommend universal formal screening, whereas UK NICE guidance favours the two Whooley questions with EPDS as an adjunct rather than universal scale-based screening.
perinatal depression screening and diagnostic assessment NCIT:C15220 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:19188538 SUPPORT Human Clinical
"Symptoms of PPD were assessed at a mean (SD) of 8.7 (2.94) weeks after delivery with the Edinburgh Postnatal Depression Scale."
Documents use of the EPDS as the standard instrument for ascertaining postpartum depressive symptoms in research cohorts.
PMID:34190962 SUPPORT Human Clinical
"with PPD (major depressive episode beginning third trimester or ≤4 weeks postdelivery), and baseline 17-item Hamilton Rating Scale for Depression (HAMD-17) score of 26 or higher"
Shows the operational case definition used in registrational trials: a major depressive episode with third-trimester or early-postpartum onset, severity-graded by HAMD-17.
📊

Prevalence

3
Worldwide
Point Prevalence 17220.0 per 100,000 >1 in 1,000
Pooled estimate across 565 studies from 80 countries or regions; 17.22% (95% CI 16.00-18.51).
Show evidence (1 reference)
PMID:34671011 SUPPORT Human Clinical
"Postpartum depression was found in 17.22% (95% CI 16.00-18.51) of the world's population."
Global pooled prevalence of postpartum depression from the largest published synthesis.
Worldwide, perinatal period
Period Prevalence 11900.0 per 100,000 (11400.0–12500.0) >1 in 1,000
Pooled perinatal (antenatal plus postnatal) depression prevalence, 11.9% (95% CI 11.4-12.5), from 140 prevalence estimates across 96 studies.
Show evidence (1 reference)
PMID:28531848 SUPPORT Human Clinical
"The overall pooled prevalence was 11.9% of women during the perinatal period (95% CI 11.4-12.5)."
Meta-analytic pooled prevalence for perinatal depression, the broader window encompassing PPD.
Southern Africa
Point Prevalence 39960.0 per 100,000 >1 in 1,000
Highest regional rate identified in the global mapping analysis (39.96%).
Show evidence (1 reference)
PMID:34671011 SUPPORT Human Clinical
"Varied prevalence rates were noted in geographic regions with the highest rate found in Southern Africa (39.96%)."
Documents the extreme upper end of regional variation in PPD prevalence.
🌍

Epidemiology

1
Geographic and socioeconomic variation
PPD prevalence varies several-fold by region and national income level, with the lowest rates in developed and high-income countries and the highest in Southern Africa. Study size and country development level are the dominant sources of between-study heterogeneity, and measurement method matters: symptom scales yield significantly higher estimates than diagnostic instruments.
Show evidence (2 references)
PMID:34671011 SUPPORT Human Clinical
"Of interested was a significantly lower rate of PPD in developed countries or high-income countries or areas."
Documents the development/income gradient in postpartum depression prevalence.
PMID:28531848 SUPPORT Human Clinical
"prevalence derived using symptom scales was significantly higher than prevalence derived using diagnostic instruments"
Establishes ascertainment method as a systematic source of variation in reported prevalence, relevant when comparing estimates across studies.
🔬

Clinical Trials

3
NCT02942004 PHASE_III COMPLETED
Phase 3 trial of brexanolone injection in women with severe postpartum depression (qualifying HAM-D score >=26), randomised 1:1:1 to brexanolone 90 mcg/kg/h, brexanolone 60 mcg/kg/h, or placebo by 60-hour continuous infusion, with change from baseline in 17-item HAM-D at 60 hours as the primary endpoint.
Show evidence (1 reference)
PMID:30177236 SUPPORT Human Clinical
"The trials have been completed and are registered with ClinicalTrials.gov, numbers NCT02942004 (study 1) and NCT02942017 (study 2)."
Registry identifiers and completion status for the two phase 3 brexanolone trials.
NCT02978326 PHASE_III COMPLETED
ROBIN, a phase 3 double-blind outpatient placebo-controlled trial of oral zuranolone 30 mg once daily for 14 days in women with PPD and baseline HAMD-17 >=26, conducted at 27 US sites, with change from baseline in HAMD-17 at day 15 as the primary endpoint.
Show evidence (1 reference)
PMID:34190962 SUPPORT Human Clinical
"TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02978326."
Registry identifier for the phase 3 zuranolone 30 mg trial.
NCT04442503 PHASE_III COMPLETED
SKYLARK, the registrational phase 3 trial of oral zuranolone 50 mg once daily for 14 days in women with severe postpartum depression, randomised 1:1 against placebo with change from baseline in 17-item HAM-D at day 15 as the primary endpoint. This is the trial supporting the dose and duration of the only PPD-specific pharmacotherapy still on the market.
Target Phenotypes: Depression HP:0000716 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Depression (HP:0000716). HP:0000716 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
clinicaltrials:NCT04442503 SUPPORT
"The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo."
ClinicalTrials.gov summary for SKYLARK (SAGE-217 is the development code for zuranolone), the registrational trial for the 50 mg dose.
PMID:37491938 SUPPORT Human Clinical
"In this double-blind phase 3 trial, women with severe PPD were randomized in a 1:1 ratio to receive zuranolone 50 mg/day or placebo for 14 days."
Primary publication of the SKYLARK trial, describing its design.
{ }

Source YAML

click to show 
name: Postpartum Depression
creation_date: '2026-08-02T12:00:00Z'
category: Psychiatric
synonyms:
- postnatal depression
- PPD
- depressive episode with postpartum onset
- major depressive episode with peripartum onset
description: >-
  Postpartum depression (PPD) is a major depressive episode with onset during
  pregnancy or in the weeks to months following delivery. It is the most common
  medical complication of childbirth, affecting roughly one in eight women in
  high-income settings and substantially more in low- and middle-income
  countries, and it carries consequences for the mother, the mother-infant
  relationship, and infant cognitive and behavioral development. PPD is
  distinguished from other major depressive episodes by a reproductive-endocrine
  trigger: the supraphysiologic gonadal steroid levels of late pregnancy fall
  precipitously at parturition, and in a susceptible subgroup of women this
  withdrawal of progesterone-derived neurosteroids — chiefly allopregnanolone,
  a positive allosteric modulator of GABA-A receptors — precipitates depression.
  This mechanism is unusually well validated for a psychiatric disorder, because
  it has been tested experimentally by hormone withdrawal in humans, modeled
  genetically in mice, and exploited therapeutically: brexanolone and zuranolone,
  both neuroactive-steroid GABA-A positive allosteric modulators, were developed
  directly from it. Zuranolone, taken orally for 14 days, is the surviving
  mechanism-matched treatment; brexanolone, the intravenous forerunner that
  proved the principle, was withdrawn from the market in April 2025 for
  commercial rather than efficacy reasons. Hypothalamic-pituitary-adrenal axis
  dysregulation, inflammatory signaling, and heritable differences in
  estrogen-driven epigenetic reprogramming contribute additional risk.
disease_term:
  preferred_term: postpartum depression
  term:
    id: MONDO:0005929
    label: postpartum depression
parents:
- depressive disorder
- puerperal disorder
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
mechanistic_hypotheses:
- hypothesis_group_id: neurosteroid_withdrawal_model
  hypothesis_label: Neurosteroid (allopregnanolone) withdrawal and GABA-A receptor plasticity failure
  status: CANONICAL
  description: >-
    The dominant model holds that PPD is triggered by the precipitous fall in
    progesterone-derived neurosteroids at parturition, acting on GABA-A
    receptors whose subunit composition has been remodeled across pregnancy.
    Women who fail to re-adapt receptor stoichiometry to the new neurosteroid
    milieu experience a loss of inhibitory tone and depressive symptoms. The
    model is supported by an experimental human hormone-withdrawal paradigm, by
    a genetic mouse model of failed GABA-A delta-subunit regulation, and — most
    persuasively — by the efficacy of two neuroactive-steroid GABA-A positive
    allosteric modulators developed directly from it.
  evidence:
  - reference: PMID:10831472
    reference_title: Effects of gonadal steroids in women with a history of postpartum depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The data provide direct evidence in support of the involvement of the
      reproductive hormones estrogen and progesterone in the development of
      postpartum depression in a subgroup of women
    explanation: >-
      Experimental simulation of pregnancy-level steroids followed by blinded
      withdrawal provides the direct human causal test underpinning the
      withdrawal model.
  - reference: PMID:28619476
    reference_title: "Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Post-partum depression is a serious mood disorder in women that might be
      triggered by peripartum fluctuations in reproductive hormones.
    explanation: >-
      States the hormonal-fluctuation trigger hypothesis that motivated
      allopregnanolone replacement as a therapeutic strategy.
- hypothesis_group_id: hpa_axis_crh_model
  hypothesis_label: Placental CRH-driven HPA axis dysregulation
  status: ALTERNATIVE
  description: >-
    A complementary model attributes PPD risk to dysregulation of the
    hypothalamic-pituitary-adrenal axis. Placental corticotropin-releasing
    hormone rises exponentially across gestation and suppresses hypothalamic
    CRH; its abrupt withdrawal after delivery leaves a transiently hyporesponsive
    axis. Accelerated mid-gestation pCRH trajectories predict postpartum
    depressive symptoms independently of prenatal mood, and notably without
    parallel cortisol or ACTH signals, suggesting a placental rather than
    adrenal locus.
  evidence:
  - reference: PMID:19188538
    reference_title: Risk of postpartum depressive symptoms with elevated corticotropin-releasing hormone in human pregnancy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Growth curve analyses indicated that the trajectories of pCRH in women
      with PPD symptoms are significantly accelerated from 23 to 26 weeks' GA.
    explanation: >-
      Longitudinal cohort evidence that a placental CRH trajectory, not a
      cortisol/ACTH signal, marks women who develop postpartum depressive
      symptoms.
pathophysiology:
- name: Gestational Neurosteroid Surge
  biological_scale: ORGANISM
  description: >-
    Across pregnancy, placental and ovarian steroidogenesis raises circulating
    progesterone and its 5-alpha-reduced neurosteroid metabolite allopregnanolone
    to supraphysiologic levels. This is the rising limb, and it is a normal
    feature of every pregnancy — it is pathogenic only as the setup for the fall
    that follows, by remodeling GABA-A receptors to a high-neurosteroid
    environment that will not persist.
  biological_processes:
  - preferred_term: steroid biosynthetic process
    term:
      id: GO:0006694
      label: steroid biosynthetic process
    modifier: INCREASED
  evidence:
  - reference: PMID:18667149
    reference_title: "GABA(A)R plasticity during pregnancy: relevance to postpartum depression."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The large increase in progesterone-derived neurosteroids during pregnancy
      and their precipitous decline at parturition may have considerable effects
      on GABA(A)Rs during pregnancy and postpartum.
    explanation: >-
      Establishes the gestational rise in progesterone-derived neurosteroids as
      the first limb of the surge-and-withdrawal cycle.
  downstream:
  - target: Precipitous Postpartum Neurosteroid Withdrawal
    causal_link_type: DIRECT
    hypothesis_groups:
    - neurosteroid_withdrawal_model
    description: >-
      Delivery of the placenta removes the source that sustained the surge,
      converting the rising limb into the steepest neurosteroid fall in normal
      human physiology.
  - target: Failure of GABA-A Receptor Subunit Plasticity
    causal_link_type: DIRECT
    hypothesis_groups:
    - neurosteroid_withdrawal_model
    description: >-
      Sustained high neurosteroid exposure across gestation is the stimulus that
      drives homeostatic remodeling of GABA-A receptor subunit composition.
- name: Precipitous Postpartum Neurosteroid Withdrawal
  biological_scale: ORGANISM
  description: >-
    Delivery of the placenta removes the dominant source of progesterone-derived
    neurosteroid within hours, producing the steepest neurosteroid withdrawal in
    normal human physiology. The withdrawal itself is universal; what
    distinguishes women who develop PPD is differential sensitivity to it,
    established experimentally by inducing and then withdrawing pregnancy-level
    estradiol and progesterone under double-blind conditions.
  biological_processes:
  - preferred_term: steroid biosynthetic process
    term:
      id: GO:0006694
      label: steroid biosynthetic process
    modifier: DECREASED
  - preferred_term: response to progesterone
    term:
      id: GO:0032570
      label: response to progesterone
    modifier: ABNORMAL
  evidence:
  - reference: PMID:10831472
    reference_title: Effects of gonadal steroids in women with a history of postpartum depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Five of the eight women with a history of postpartum depression (62.5%)
      and none of the eight women in the comparison group developed significant
      mood symptoms during the withdrawal period.
    explanation: >-
      Blinded withdrawal of simulated pregnancy-level steroids reproduced mood
      symptoms only in women with a PPD history, isolating steroid withdrawal
      as the proximate trigger.
  - reference: PMID:10831472
    reference_title: Effects of gonadal steroids in women with a history of postpartum depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      they suggest that women with a history of postpartum depression are
      differentially sensitive to mood-destabilizing effects of gonadal steroids
    explanation: >-
      Establishes differential steroid sensitivity, rather than an abnormal
      hormone concentration, as the susceptibility trait.
  downstream:
  - target: Failure of GABA-A Receptor Subunit Plasticity
    causal_link_type: DIRECT
    hypothesis_groups:
    - neurosteroid_withdrawal_model
    description: >-
      The fall in neurosteroid is what exposes any failure to re-adapt receptor
      stoichiometry: a receptor population tuned to the gestational milieu
      becomes mismatched the moment that milieu disappears.
  - target: Estrogen-Sensitive Epigenetic Reprogramming in Susceptible Women
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Estrogen-receptor-mediated transcriptional and DNA methylation changes in hippocampus.
    description: >-
      The same perinatal steroid excursion drives estrogen-responsive epigenetic
      reprogramming, which appears altered in women who go on to develop PPD.
- name: Failure of GABA-A Receptor Subunit Plasticity
  biological_scale: CELLULAR
  description: >-
    GABA-A receptors normally adapt to the pregnancy neurosteroid environment by
    downregulating delta and gamma2 subunits, then rebounding immediately
    postpartum as neurosteroid levels fall. Delta-subunit-containing
    extrasynaptic receptors mediate tonic inhibition and are the principal
    neurosteroid-sensitive population, while gamma2-containing synaptic
    receptors mediate phasic inhibition. Mice genetically unable to perform the
    delta-subunit adaptation develop depression-like and abnormal maternal
    behavior, identifying failed receptor plasticity — rather than the hormone
    change itself — as the pathogenic step.
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  - preferred_term: hippocampal neuron
    term:
      id: CL:0002608
      label: hippocampal neuron
  biological_processes:
  - preferred_term: regulation of postsynaptic membrane neurotransmitter receptor levels
    term:
      id: GO:0099072
      label: regulation of postsynaptic membrane neurotransmitter receptor levels
    modifier: ABNORMAL
  - preferred_term: gamma-aminobutyric acid signaling pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:18667149
    reference_title: "GABA(A)R plasticity during pregnancy: relevance to postpartum depression."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Here we show a significant decrease in tonic and phasic inhibitions in
      pregnant mice, mediated by a downregulation of GABA(A)R delta and gamma2
      subunits, respectively, which rebounds immediately postpartum.
    explanation: >-
      Demonstrates the physiological receptor-remodeling program across
      pregnancy and its postpartum rebound in a mouse model.
  - reference: PMID:18667149
    reference_title: "GABA(A)R plasticity during pregnancy: relevance to postpartum depression."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Mice which do not exhibit GABA(A)R delta subunit regulation throughout
      pregnancy (Gabrd(+/-) and Gabrd(-/-)) exhibit depression-like and abnormal
      maternal behaviors, resulting in reduced pup survival.
    explanation: >-
      Genetic loss of delta-subunit plasticity is sufficient to produce a
      PPD-like behavioral phenotype, supporting causality of the plasticity
      failure.
  downstream:
  - target: Loss of GABAergic Inhibitory Tone
    causal_link_type: DIRECT
    hypothesis_groups:
    - neurosteroid_withdrawal_model
    description: >-
      Mismatched receptor subunit composition leaves inhibitory signaling
      inadequate for the abruptly neurosteroid-depleted postpartum brain.
- name: Loss of GABAergic Inhibitory Tone
  biological_scale: CELLULAR
  description: >-
    The net consequence of neurosteroid withdrawal against a maladapted receptor
    population is reduced tonic and phasic GABAergic inhibition in
    limbic circuits regulating mood and maternal behavior. This node is the
    convergent target of both approved mechanism-matched drugs, which restore
    positive allosteric modulation at synaptic and extrasynaptic GABA-A
    receptors. Its therapeutic reversibility is the strongest evidence that the
    node is causal rather than correlative.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: inhibitory postsynaptic potential
    term:
      id: GO:0060080
      label: inhibitory postsynaptic potential
    modifier: DECREASED
  - preferred_term: gamma-aminobutyric acid signaling pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:18667149
    reference_title: "GABA(A)R plasticity during pregnancy: relevance to postpartum depression."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These abnormal postpartum behaviors were ameliorated in Gabrd(+/-) mice by
      a GABA(A)R delta-subunit-selective agonist, THIP.
    explanation: >-
      Pharmacological restoration of delta-subunit-mediated tonic inhibition
      rescues the PPD-like phenotype, establishing loss of inhibitory tone as
      the proximate and reversible lesion.
  - reference: PMID:30177236
    reference_title: "Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We assessed brexanolone injection (formerly SAGE-547 injection), a
      positive allosteric modulator of γ-aminobutyric-acid type A (GABAA)
      receptors, for the treatment of moderate to severe post-partum depression.
    explanation: >-
      Human phase 3 program built on restoring GABA-A positive allosteric
      modulation, translating the inhibitory-tone node into therapy.
  downstream:
  - target: Postpartum Major Depressive Episode
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - neurosteroid_withdrawal_model
    intermediate_mechanisms:
    - Limbic and corticolimbic circuit dysfunction consequent to reduced inhibitory tone.
    description: >-
      Reduced inhibitory control in mood-regulating circuits manifests as the
      depressive syndrome; restoring GABA-A modulation reverses it within days.
- name: Placental CRH Elevation
  biological_scale: ORGANISM
  description: >-
    The placenta secretes corticotropin-releasing hormone in exponentially
    rising quantities across gestation. Unlike hypothalamic CRH, placental CRH
    is upregulated rather than suppressed by cortisol, creating a feed-forward
    loop. Women whose mid-gestation pCRH rises fastest are at elevated risk of
    postpartum depressive symptoms — an association that holds after adjusting
    for prenatal depressive symptoms.
  biological_processes:
  - preferred_term: cellular response to corticotropin-releasing hormone stimulus
    term:
      id: GO:0071376
      label: cellular response to corticotropin-releasing hormone stimulus
    modifier: INCREASED
  evidence:
  - reference: PMID:19188538
    reference_title: Risk of postpartum depressive symptoms with elevated corticotropin-releasing hormone in human pregnancy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Growth curve analyses indicated that the trajectories of pCRH in women
      with PPD symptoms are significantly accelerated from 23 to 26 weeks' GA.
    explanation: >-
      Identifies an accelerated mid-gestation pCRH trajectory, rather than a
      single elevated value, as the risk-marking feature.
  - reference: PMID:19188538
    reference_title: Risk of postpartum depressive symptoms with elevated corticotropin-releasing hormone in human pregnancy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At 25 weeks' GA, pCRH was a strong predictor of PPD symptoms
    explanation: >-
      Prospective cohort finding that mid-gestation placental CRH predicts
      postpartum depressive symptoms.
  downstream:
  - target: Postpartum HPA Axis Hyporesponsiveness
    causal_link_type: DIRECT
    hypothesis_groups:
    - hpa_axis_crh_model
    description: >-
      Sustained placental CRH suppresses maternal hypothalamic CRH output; its
      abrupt removal at delivery leaves the axis transiently unable to respond.
- name: Postpartum HPA Axis Hyporesponsiveness
  biological_scale: ORGANISM
  description: >-
    Placental delivery abruptly removes the dominant CRH source, leaving a
    transiently hyporesponsive hypothalamic-pituitary-adrenal axis while
    suppressed hypothalamic CRH output recovers. Notably the risk signal in
    human data attaches to placental CRH and is not mirrored by cortisol or
    ACTH, which constrains this arm to a placental rather than adrenal locus.
  biological_processes:
  - preferred_term: cellular response to corticotropin-releasing hormone stimulus
    term:
      id: GO:0071376
      label: cellular response to corticotropin-releasing hormone stimulus
    modifier: DYSREGULATED
  evidence:
  - reference: PMID:19188538
    reference_title: Risk of postpartum depressive symptoms with elevated corticotropin-releasing hormone in human pregnancy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No significant associations were found for cortisol and ACTH.
    explanation: >-
      Constrains the mechanism to a placental CRH signal rather than generalized
      adrenal HPA overactivity, and limits how far the HPA model can be extended.
  downstream:
  - target: Postpartum Major Depressive Episode
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    hypothesis_groups:
    - hpa_axis_crh_model
    description: >-
      The intermediates linking an accelerated pCRH trajectory to depressive
      symptom onset are not established in humans; the association is
      predictive rather than mechanistically resolved.
- name: Estrogen-Sensitive Epigenetic Reprogramming in Susceptible Women
  biological_scale: MOLECULAR
  description: >-
    Susceptibility to PPD appears to reside partly in how a woman's genome
    responds epigenetically to the perinatal estrogen excursion, rather than in
    the size of the excursion itself. Antenatal blood DNA methylation at
    estrogen-responsive loci — identified by cross-referencing human prospective
    profiles with hippocampal methylation changes induced by 17-beta-estradiol
    in mice — discriminates women who will develop PPD, with HP1BP3 and TTC9B
    as the two replicated biomarker loci. This provides a molecular correlate
    for the differential steroid sensitivity demonstrated experimentally.
  cell_types:
  - preferred_term: hippocampal neuron
    term:
      id: CL:0002608
      label: hippocampal neuron
  biological_processes:
  - preferred_term: cellular response to estrogen stimulus
    term:
      id: GO:0071391
      label: cellular response to estrogen stimulus
    modifier: ABNORMAL
  evidence:
  - reference: PMID:23689534
    reference_title: Antenatal prediction of postpartum depression with blood DNA methylation biomarkers.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DNA methylation associated with PPD risk correlated significantly with
      E2-induced DNA methylation change, suggesting an enhanced sensitivity to
      estrogen-based DNA methylation reprogramming exists in those at risk for
      PPD
    explanation: >-
      Cross-species design linking altered estrogen-driven epigenetic
      reprogramming to PPD risk, giving a molecular basis for differential
      hormone sensitivity.
  - reference: PMID:23689534
    reference_title: Antenatal prediction of postpartum depression with blood DNA methylation biomarkers.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we identified two biomarker loci at the HP1BP3 and TTC9B genes that
      predicted PPD with an area under the receiver operator characteristic
      (ROC) curve (area under the curve (AUC)) of 0.87 in antenatally euthymic
      women
    explanation: >-
      Identifies the specific replicated loci and quantifies antenatal
      predictive performance in euthymic women.
  downstream:
  - target: Postpartum Major Depressive Episode
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Epigenetic sensitivity is a susceptibility modifier; the pathway from
      methylation state to symptom onset is not resolved.
- name: Postpartum Major Depressive Episode
  biological_scale: ORGANISM
  description: >-
    The convergent clinical endpoint: a major depressive episode with peripartum
    onset, comprising depressed mood, anhedonia, sleep and appetite disturbance,
    impaired concentration, anxiety, and in severe cases suicidal ideation.
    Beyond the mother, the episode disrupts maternal-infant bonding and is
    associated with adverse infant cognitive and behavioral outcomes. Rapid
    reversibility with neuroactive-steroid therapy — meaningful separation from
    placebo by day 3 — distinguishes the syndrome pharmacodynamically from
    non-puerperal major depression treated with monoaminergic agents.
  biological_processes:
  - preferred_term: gamma-aminobutyric acid signaling pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:34190962
    reference_title: "Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Postpartum depression (PPD) is one of the most common medical
      complications during and after pregnancy, negatively affecting both mother
      and child.
    explanation: >-
      Frames the clinical endpoint and its two-generation impact.
  - reference: PMID:34190962
    reference_title: "Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sustained differences in HAMD-17 scores favoring zuranolone were observed
      from day 3
    explanation: >-
      Documents onset of benefit by day 3, the rapid pharmacodynamic signature
      of neurosteroid replacement in this syndrome.
phenotypes:
- category: Clinical
  name: Depressed mood
  description: >-
    Persistent depressed mood with peripartum onset is the defining feature,
    assessed in trials with the 17-item Hamilton Rating Scale for Depression and
    in screening with the Edinburgh Postnatal Depression Scale.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:37491938
    reference_title: Zuranolone for the Treatment of Postpartum Depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Postpartum depression (PPD) is a common perinatal complication with
      adverse maternal and infant outcomes.
    explanation: >-
      Confirms the depressive syndrome as the defining clinical presentation
      of the disorder.
- category: Clinical
  name: Anhedonia
  description: >-
    Loss of interest or pleasure, including diminished pleasure in interaction
    with the infant, is a core depressive symptom domain in PPD.
  phenotype_term:
    preferred_term: Anhedonia
    term:
      id: HP:0012154
      label: Anhedonia
- category: Clinical
  name: Anxiety
  description: >-
    Comorbid anxiety is prominent in PPD and often centers on infant safety.
    Zuranolone trials measured it with the Hamilton Rating Scale for Anxiety and
    showed improvement alongside depressive symptoms.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:34190962
    reference_title: "Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hamilton Rating Scale for Anxiety score (difference, -3.9; 95% CI, -6.7 to
      -1.1; P = .006)
    explanation: >-
      Anxiety was a prespecified secondary endpoint that improved with
      treatment, documenting it as a component of the PPD phenotype.
- category: Clinical
  name: Insomnia
  description: >-
    Sleep disturbance that exceeds the sleep fragmentation expected from infant
    care — notably inability to sleep when the infant sleeps — is characteristic
    and is one of the harder symptoms to disentangle from normal postpartum
    physiology.
  phenotype_term:
    preferred_term: Insomnia
    term:
      id: HP:0100785
      label: Insomnia
- category: Clinical
  name: Fatigue
  description: >-
    Profound fatigue and loss of energy beyond expected postpartum recovery.
  phenotype_term:
    preferred_term: Fatigue
    term:
      id: HP:0012378
      label: Fatigue
- category: Clinical
  name: Irritability
  description: >-
    Irritability and mood lability are frequently the presenting complaint,
    sometimes more prominent than reported sadness.
  phenotype_term:
    preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
- category: Clinical
  name: Poor appetite
  description: >-
    Appetite and weight change form part of the neurovegetative symptom cluster.
  phenotype_term:
    preferred_term: Poor appetite
    term:
      id: HP:0004396
      label: Poor appetite
- category: Clinical
  name: Suicidal ideation
  description: >-
    Suicidal ideation occurs in severe PPD, and suicide is a leading cause of
    maternal death in the year after delivery. Trials of neuroactive steroids
    monitored suicidal ideation as a safety endpoint and reported no
    treatment-emergent increase.
  phenotype_term:
    preferred_term: Suicidal ideation
    term:
      id: HP:0031589
      label: Suicidal ideation
  evidence:
  - reference: PMID:37491938
    reference_title: Zuranolone for the Treatment of Postpartum Depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No loss of consciousness, withdrawal symptoms, or increased suicidal
      ideation or behavior were observed.
    explanation: >-
      Suicidal ideation was tracked as a safety endpoint in severe PPD,
      reflecting its clinical relevance in this population.
genetic:
- name: HP1BP3
  gene_term:
    preferred_term: HP1BP3
    term:
      id: hgnc:24973
      label: HP1BP3
  relationship_type: BIOMARKER
  association: >-
    Antenatal blood DNA methylation at HP1BP3, an estrogen-responsive locus
    identified by cross-referencing human prospective methylation profiles with
    estradiol-induced hippocampal methylation changes in mice, is one of two
    replicated biomarker loci predicting subsequent PPD.
  evidence:
  - reference: PMID:23689534
    reference_title: Antenatal prediction of postpartum depression with blood DNA methylation biomarkers.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we identified two biomarker loci at the HP1BP3 and TTC9B genes that
      predicted PPD with an area under the receiver operator characteristic
      (ROC) curve (area under the curve (AUC)) of 0.87 in antenatally euthymic
      women
    explanation: >-
      Identifies HP1BP3 methylation as an antenatal predictive biomarker locus
      for PPD.
- name: TTC9B
  gene_term:
    preferred_term: TTC9B
    term:
      id: hgnc:26395
      label: TTC9B
  relationship_type: BIOMARKER
  association: >-
    TTC9B is the second replicated estrogen-responsive methylation biomarker
    locus; combined with HP1BP3 and blood count data the model predicted PPD
    across both antenatally euthymic and antenatally depressed women.
  evidence:
  - reference: PMID:23689534
    reference_title: Antenatal prediction of postpartum depression with blood DNA methylation biomarkers.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Incorporation of blood count data into the model accounted for the
      discrepancy and produced an AUC of 0.96 across both prepartum depressed
      and euthymic women.
    explanation: >-
      Quantifies combined-model performance for the two-locus methylation
      biomarker after adjustment for blood cell composition.
- name: KCTD16
  gene_term:
    preferred_term: KCTD16
    term:
      id: hgnc:29244
      label: KCTD16
  relationship_type: SUSCEPTIBILITY
  association: >-
    A cross-trait GWAS meta-analysis of premenstrual disorder and postpartum
    depression identified a shared genome-wide significant locus in the 3'
    untranslated region of KCTD16. KCTD16 encodes one of the KCTD auxiliary
    subunits that assemble onto the GABA-B2 subunit and set the agonist potency
    and signalling kinetics of the native GABA-B receptor, so the locus
    implicates metabotropic GABA-B inhibitory signalling in postpartum
    depression. This is a different inhibitory axis from the ionotropic GABA-A
    neurosteroid mechanism the rest of this entry models. Transcriptome-wide
    association localised the regulatory signal to hippocampus, with no
    comparable signal in other brain regions or peripheral tissues.
  notes: >-
    Preprint evidence, not yet peer reviewed and not replicated in an
    independent cohort; the GABA-B assignment rests on the gene's established
    receptor role rather than on functional work in postpartum depression
    itself. Recorded as a susceptibility locus rather than woven into the
    pathophysiology chain for that reason. See the
    ppd_gabab_versus_gabaa_inhibitory_axis discussion.
  evidence:
  - reference: PPR:PPR1293935
    reference_title: "Shared Genetic Architecture of Premenstrual Disorder and Postpartum Depression: Registry-Based and Genetic Evidence"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cross-trait meta-analysis identified two novel genome-wide significant
      loci jointly associated with PMD and PPD
    explanation: >-
      Establishes KCTD16 as one of the two loci reaching genome-wide
      significance in the joint premenstrual-disorder and postpartum-depression
      analysis.
  - reference: PPR:PPR1293935
    reference_title: "Shared Genetic Architecture of Premenstrual Disorder and Postpartum Depression: Registry-Based and Genetic Evidence"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      locus implicates GABAB–mediated inhibitory signaling in both disorders
    explanation: >-
      The authors' own reading of the KCTD16 signal, naming GABA-B rather than
      GABA-A as the implicated inhibitory pathway.
  - reference: PPR:PPR1293935
    reference_title: "Shared Genetic Architecture of Premenstrual Disorder and Postpartum Depression: Registry-Based and Genetic Evidence"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      with no detectable trend effects in other brain regions or peripheral
      tissues
    explanation: >-
      Tissue specificity of the KCTD16 transcriptome-wide signal: hippocampus
      only, which is the region where the neurosteroid-sensitive GABAergic
      mechanism of this entry is also localised.
  - reference: PMID:20400944
    reference_title: Native GABA(B) receptors are heteromultimers with a family of auxiliary subunits.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      KCTD proteins 8, 12, 12b and 16 show distinct expression profiles in the
      brain and associate tightly with the carboxy terminus of GABA(B2) as
      tetramers.
    explanation: >-
      Independent basis for treating a KCTD16 locus as a GABA-B signalling
      locus: KCTD16 protein is a constituent of the native brain GABA-B
      receptor complex.
  - reference: PMID:20400944
    reference_title: Native GABA(B) receptors are heteromultimers with a family of auxiliary subunits.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      our results establish the KCTD proteins as auxiliary subunits of GABA(B)
      receptors that determine the pharmacology and kinetics of the receptor
      response
    explanation: >-
      Specifies what a change in KCTD16 dosage would be expected to alter,
      namely GABA-B receptor potency and response kinetics rather than receptor
      presence.
- name: PCDH9
  gene_term:
    preferred_term: PCDH9
    term:
      id: hgnc:8661
      label: PCDH9
  relationship_type: SUSCEPTIBILITY
  association: >-
    The second genome-wide significant locus shared between premenstrual
    disorder and postpartum depression in the same cross-trait meta-analysis
    maps to an intronic region of PCDH9, a non-clustered protocadherin. No
    mechanism linking this locus to peripartum mood regulation has been
    established, and the preprint offers none beyond the association itself.
  notes: >-
    Preprint evidence, not yet peer reviewed and not replicated. Curated as a
    positional association only; the gene has no assigned role in this entry's
    pathophysiology and none should be inferred from its inclusion here.
  evidence:
  - reference: PPR:PPR1293935
    reference_title: "Shared Genetic Architecture of Premenstrual Disorder and Postpartum Depression: Registry-Based and Genetic Evidence"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cross-trait meta-analysis identified two novel genome-wide significant
      loci jointly associated with PMD and PPD
    explanation: >-
      Establishes PCDH9 as the second of the two shared genome-wide significant
      loci; the mechanistic interpretation is left open by the authors.
environmental:
- name: Prior history of postpartum depression
  description: >-
    A previous postpartum depressive episode is among the strongest predictors
    of recurrence and identifies the hormone-sensitive subgroup that responds to
    experimental steroid withdrawal with mood symptoms.
  evidence:
  - reference: PMID:10831472
    reference_title: Effects of gonadal steroids in women with a history of postpartum depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Five of the eight women with a history of postpartum depression (62.5%)
      and none of the eight women in the comparison group developed significant
      mood symptoms during the withdrawal period.
    explanation: >-
      Prior PPD history marks differential steroid sensitivity, which is the
      trait conferring risk on re-exposure.
- name: Low- and middle-income country setting
  description: >-
    Perinatal depression prevalence is significantly higher in low- and
    middle-income countries than in high-income countries, reflecting
    socioeconomic stressors, reduced social support, and limited access to
    perinatal mental health services.
  evidence:
  - reference: PMID:28531848
    reference_title: A systematic review and meta-regression of the prevalence and incidence of perinatal depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      prevalence was significantly higher in women from low and middle income
      countries compared to women from high income countries (OR 1.8, 95% CI
      1.4-2.2)
    explanation: >-
      Meta-regression quantifying the income-setting gradient in perinatal
      depression prevalence.
treatments:
- name: Brexanolone
  description: >-
    Brexanolone is an intravenous formulation of allopregnanolone, the
    progesterone-derived neurosteroid whose postpartum withdrawal is the
    proposed trigger of PPD. Administered as a single 60-hour continuous
    infusion, it acts as a positive allosteric modulator of synaptic and
    extrasynaptic GABA-A receptors, directly replacing the withdrawn endogenous
    modulator. It was the first drug approved specifically for postpartum
    depression (FDA 2019) and remains the archetypal mechanism-matched therapy
    in this entry — the trial evidence below is what established the
    neurosteroid-replacement principle that zuranolone now delivers orally.

    WITHDRAWN FROM MARKET: brexanolone is no longer commercially available.
    Sage Therapeutics notified FDA that the product was no longer marketed and
    requested withdrawal; FDA withdrew approval of NDA 211371 as of
    2025-04-14. The 60-hour monitored intravenous infusion, the REMS
    requirement arising from a boxed warning for excessive sedation and sudden
    loss of consciousness, and the drug's cost are the widely cited practical
    reasons the product did not survive commercially. It is retained in this
    entry because its trial data remain the primary human evidence for the
    causal role of the inhibitory-tone node, not because it is a current
    treatment option.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: brexanolone
      term:
        id: CHEBI:50169
        label: brexanolone
  target_mechanisms:
  - target: Loss of GABAergic Inhibitory Tone
    treatment_effect: RESTORES
    description: >-
      Intravenous allopregnanolone restores positive allosteric modulation at
      synaptic and extrasynaptic GABA-A receptors, replacing the neurosteroid
      tone lost at parturition.
  evidence:
  - reference: PMID:28619476
    reference_title: "Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At 60 h, mean reduction in HAM-D total score from baseline was 21·0 points
      (SE 2·9) in the brexanolone group compared with 8·8 points (SE 2·8) in the
      placebo group
    explanation: >-
      Phase 2 randomised placebo-controlled trial establishing efficacy of
      allopregnanolone replacement in severe PPD.
  - reference: PMID:30177236
    reference_title: "Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In study 1, at 60 h, the least-squares (LS) mean reduction in HAM-D total
      score from baseline was 19·5 points (SE 1·2) in the BRX60 group and 17·7
      points (1·2) in the BRX90 group compared with 14·0 points (1·1) in the
      placebo group
    explanation: >-
      Two phase 3 trials confirming benefit over placebo across moderate and
      severe PPD, supporting the mechanism-matched treatment rationale.
  - reference: url:https://www.govinfo.gov/content/pkg/FR-2025-03-14/html/2025-04101.htm
    reference_title: "Federal Register, Volume 90 Issue 49 (Friday, March 14, 2025)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Therefore, approval of NDA 211371, and all amendments and supplements
      thereto, is hereby withdrawn as of April 14, 2025.
    explanation: >-
      Federal Register notice (FDA, Docket FDA-2024-N-5852) recording formal
      withdrawal of brexanolone's marketing approval. Regulatory status, not a
      study result, hence evidence_source OTHER.
  - reference: url:https://www.govinfo.gov/content/pkg/FR-2025-03-14/html/2025-04101.htm
    reference_title: "Federal Register, Volume 90 Issue 49 (Friday, March 14, 2025)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Sage notified the Agency in writing that the drug product was no longer
      marketed and requested that the approval of the application be withdrawn.
    explanation: >-
      Establishes that withdrawal was a commercial decision by the sponsor, not
      an efficacy or safety revocation by FDA — the distinction matters for
      interpreting the trial evidence above, which stands unaffected.
- name: Zuranolone
  description: >-
    Zuranolone is an orally bioavailable neuroactive steroid and positive
    allosteric modulator of synaptic and extrasynaptic GABA-A receptors, given
    as a once-daily 14-day course. It applies the same neurosteroid-replacement
    logic as brexanolone without requiring a 60-hour monitored intravenous
    infusion, and separates from placebo by day 3.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: zuranolone
      term:
        id: CHEBI:228302
        label: zuranolone
  target_mechanisms:
  - target: Loss of GABAergic Inhibitory Tone
    treatment_effect: RESTORES
    description: >-
      Oral neuroactive steroid restoring positive allosteric modulation at
      synaptic and extrasynaptic GABA-A receptors.
  evidence:
  - reference: PMID:37491938
    reference_title: Zuranolone for the Treatment of Postpartum Depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Treatment with zuranolone compared with placebo resulted in statistically
      significant improvement in depressive symptoms at day 15
    explanation: >-
      Phase 3 SKYLARK trial of zuranolone 50 mg in severe PPD demonstrating
      efficacy on the primary endpoint.
  - reference: PMID:34190962
    reference_title: "Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Zuranolone demonstrated significant day 15 HAMD-17 score improvements from
      baseline vs placebo (-17.8 vs -13.6; difference, -4.2; 95% CI, -6.9 to
      -1.5; P = .003).
    explanation: >-
      Earlier phase 3 trial of zuranolone 30 mg confirming benefit on the
      primary HAMD-17 endpoint.
- name: Selective serotonin reuptake inhibitor therapy
  description: >-
    SSRIs such as sertraline remain a mainstay of PPD pharmacotherapy,
    particularly outside the acute severe presentations studied in the
    neuroactive-steroid trials. They act on monoaminergic rather than
    neurosteroid-GABAergic mechanisms and have a slower onset, and are therefore
    not linked to a pathophysiology node in this entry.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sertraline
      term:
        id: CHEBI:9123
        label: sertraline
- name: Psychotherapy
  description: >-
    Structured psychotherapies, principally cognitive behavioral therapy and
    interpersonal psychotherapy, are first-line for mild to moderate PPD and are
    used alongside pharmacotherapy in severe disease.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Psychotherapy
    term:
      id: NCIT:C15308
      label: Psychotherapy
prevalence:
- population: Worldwide
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 17220.0
  notes: >-
    Pooled estimate across 565 studies from 80 countries or regions; 17.22%
    (95% CI 16.00-18.51).
  evidence:
  - reference: PMID:34671011
    reference_title: Mapping global prevalence of depression among postpartum women.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Postpartum depression was found in 17.22% (95% CI 16.00-18.51) of the
      world's population.
    explanation: >-
      Global pooled prevalence of postpartum depression from the largest
      published synthesis.
- population: Worldwide, perinatal period
  measure_type: PERIOD_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 11900.0
  rate_low: 11400.0
  rate_high: 12500.0
  notes: >-
    Pooled perinatal (antenatal plus postnatal) depression prevalence, 11.9%
    (95% CI 11.4-12.5), from 140 prevalence estimates across 96 studies.
  evidence:
  - reference: PMID:28531848
    reference_title: A systematic review and meta-regression of the prevalence and incidence of perinatal depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The overall pooled prevalence was 11.9% of women during the perinatal
      period (95% CI 11.4-12.5).
    explanation: >-
      Meta-analytic pooled prevalence for perinatal depression, the broader
      window encompassing PPD.
- population: Southern Africa
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 39960.0
  notes: Highest regional rate identified in the global mapping analysis (39.96%).
  evidence:
  - reference: PMID:34671011
    reference_title: Mapping global prevalence of depression among postpartum women.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Varied prevalence rates were noted in geographic regions with the highest
      rate found in Southern Africa (39.96%).
    explanation: >-
      Documents the extreme upper end of regional variation in PPD prevalence.
epidemiology:
- name: Geographic and socioeconomic variation
  description: >-
    PPD prevalence varies several-fold by region and national income level, with
    the lowest rates in developed and high-income countries and the highest in
    Southern Africa. Study size and country development level are the dominant
    sources of between-study heterogeneity, and measurement method matters:
    symptom scales yield significantly higher estimates than diagnostic
    instruments.
  evidence:
  - reference: PMID:34671011
    reference_title: Mapping global prevalence of depression among postpartum women.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of interested was a significantly lower rate of PPD in developed countries
      or high-income countries or areas.
    explanation: >-
      Documents the development/income gradient in postpartum depression
      prevalence.
  - reference: PMID:28531848
    reference_title: A systematic review and meta-regression of the prevalence and incidence of perinatal depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      prevalence derived using symptom scales was significantly higher than
      prevalence derived using diagnostic instruments
    explanation: >-
      Establishes ascertainment method as a systematic source of variation in
      reported prevalence, relevant when comparing estimates across studies.
clinical_trials:
- name: NCT02942004
  phase: PHASE_III
  status: COMPLETED
  description: >-
    Phase 3 trial of brexanolone injection in women with severe postpartum
    depression (qualifying HAM-D score >=26), randomised 1:1:1 to brexanolone
    90 mcg/kg/h, brexanolone 60 mcg/kg/h, or placebo by 60-hour continuous
    infusion, with change from baseline in 17-item HAM-D at 60 hours as the
    primary endpoint.
  evidence:
  - reference: PMID:30177236
    reference_title: "Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The trials have been completed and are registered with ClinicalTrials.gov,
      numbers NCT02942004 (study 1) and NCT02942017 (study 2).
    explanation: >-
      Registry identifiers and completion status for the two phase 3
      brexanolone trials.
- name: NCT02978326
  phase: PHASE_III
  status: COMPLETED
  description: >-
    ROBIN, a phase 3 double-blind outpatient placebo-controlled trial of oral
    zuranolone 30 mg once daily for 14 days in women with PPD and baseline
    HAMD-17 >=26, conducted at 27 US sites, with change from baseline in
    HAMD-17 at day 15 as the primary endpoint.
  evidence:
  - reference: PMID:34190962
    reference_title: "Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02978326.
    explanation: >-
      Registry identifier for the phase 3 zuranolone 30 mg trial.
- name: NCT04442503
  phase: PHASE_III
  status: COMPLETED
  description: >-
    SKYLARK, the registrational phase 3 trial of oral zuranolone 50 mg once
    daily for 14 days in women with severe postpartum depression, randomised
    1:1 against placebo with change from baseline in 17-item HAM-D at day 15 as
    the primary endpoint. This is the trial supporting the dose and duration of
    the only PPD-specific pharmacotherapy still on the market.
  target_phenotypes:
  - preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: clinicaltrials:NCT04442503
    reference_title: "A Randomized, Double-Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of SAGE-217 in the Treatment of Adults With Severe Postpartum Depression"
    supports: SUPPORT
    snippet: >-
      The purpose of this study is to determine if treatment with SAGE-217
      reduces depressive symptoms in females with severe postpartum depression
      (PPD) as compared to placebo.
    explanation: >-
      ClinicalTrials.gov summary for SKYLARK (SAGE-217 is the development code
      for zuranolone), the registrational trial for the 50 mg dose.
  - reference: PMID:37491938
    reference_title: Zuranolone for the Treatment of Postpartum Depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this double-blind phase 3 trial, women with severe PPD were randomized
      in a 1:1 ratio to receive zuranolone 50 mg/day or placebo for 14 days.
    explanation: >-
      Primary publication of the SKYLARK trial, describing its design.
diagnosis:
- name: Perinatal depression screening
  description: >-
    PPD is diagnosed clinically against DSM-5 major depressive episode criteria
    with the peripartum-onset specifier; there is no PPD-specific diagnostic
    algorithm. Case detection therefore rests on screening instruments — the
    Edinburgh Postnatal Depression Scale, a 10-item perinatal-specific
    self-report measure that also captures anxiety items, and the PHQ-9, both
    validated in this population. Screening policy diverges internationally:
    US bodies recommend universal formal screening, whereas UK NICE guidance
    favours the two Whooley questions with EPDS as an adjunct rather than
    universal scale-based screening.
  diagnosis_term:
    preferred_term: perinatal depression screening and diagnostic assessment
    term:
      id: NCIT:C15220
      label: Diagnosis Assessment
  evidence:
  - reference: PMID:19188538
    reference_title: Risk of postpartum depressive symptoms with elevated corticotropin-releasing hormone in human pregnancy.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Symptoms of PPD were assessed at a mean (SD) of 8.7 (2.94) weeks after
      delivery with the Edinburgh Postnatal Depression Scale.
    explanation: >-
      Documents use of the EPDS as the standard instrument for ascertaining
      postpartum depressive symptoms in research cohorts.
  - reference: PMID:34190962
    reference_title: "Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      with PPD (major depressive episode beginning third trimester or ≤4 weeks
      postdelivery), and baseline 17-item Hamilton Rating Scale for Depression
      (HAMD-17) score of 26 or higher
    explanation: >-
      Shows the operational case definition used in registrational trials: a
      major depressive episode with third-trimester or early-postpartum onset,
      severity-graded by HAMD-17.
discussions:
- discussion_id: ppd_hormone_concentration_null_findings
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Precipitous Postpartum Neurosteroid Withdrawal
  prompt: >-
    If PPD is caused by perinatal reproductive hormone change, why do many
    studies fail to find any difference in hormone concentrations between women
    who develop PPD and those who do not?
  rationale: >-
    The withdrawal model is not a claim about hormone levels but about
    differential sensitivity to a hormone change that all postpartum women
    experience. Correlational studies comparing absolute concentrations are
    therefore underpowered to detect the mechanism by construction, and their
    null results have repeatedly been misread as refuting the model. Resolving
    this requires sensitivity-stratified rather than concentration-stratified
    designs — the logic of the experimental withdrawal paradigm and of the
    estrogen-responsive methylation biomarker work.
  evidence:
  - reference: PMID:25263255
    reference_title: The role of reproductive hormones in postpartum depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although a number of human and nonhuman animal studies support the role of
      reproductive hormones in PPD, several studies have failed to detect an
      association between hormone concentrations and PPD.
    explanation: >-
      States the discrepancy directly: mechanistic support coexists with null
      concentration-association findings.
  - reference: PMID:25263255
    reference_title: The role of reproductive hormones in postpartum depression.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Reproductive hormones influence virtually every biological system
      implicated in PPD, and a subgroup of women seem to be particularly
      sensitive to the effects of perinatal changes in hormone levels.
    explanation: >-
      Articulates the hormone-sensitive-subgroup resolution that reconciles the
      positive mechanistic and null correlational literatures.
- discussion_id: ppd_gabrd_mouse_translation
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Failure of GABA-A Receptor Subunit Plasticity
  prompt: >-
    Does the Gabrd mouse model's failed GABA-A delta-subunit plasticity
    correspond to a demonstrable receptor-remodeling defect in women with
    postpartum depression?
  rationale: >-
    The subunit-plasticity step is the mechanistic core of the canonical model,
    yet the direct evidence for it is entirely murine: delta and gamma2
    downregulation across pregnancy with postpartum rebound, and a depression-like
    phenotype in Gabrd heterozygotes and nulls. Human support is indirect,
    inferred from the therapeutic efficacy of GABA-A positive allosteric
    modulators, which would also be expected if the receptor population were
    normal and only the ligand were withdrawn. Distinguishing failed receptor
    plasticity from simple ligand withdrawal matters because it determines
    whether PPD susceptibility is a receptor trait or a steroid-metabolism trait,
    and hence whether prophylaxis should target receptor adaptation or
    neurosteroid maintenance.
  proposed_experiments:
  - experiment_id: exp_ppd_human_gabaa_subunit_trajectory
    name: Human GABA-A delta/gamma2 subunit trajectory across pregnancy and postpartum
    description: >-
      Quantify GABA-A delta- and gamma2-subunit expression or availability across
      late pregnancy and the early postpartum in women with and without
      postpartum depression, using PET ligands sensitive to receptor subtype
      availability and, where obtainable, postmortem or biopsy tissue. The mouse
      model predicts downregulation across pregnancy with immediate postpartum
      rebound; failure of that rebound in affected women would establish the
      plasticity step in humans.
  - experiment_id: exp_ppd_gabrd_variant_treatment_response
    name: GABRD variant stratification of neuroactive-steroid treatment response
    description: >-
      Test whether GABRD variants stratify response to brexanolone or zuranolone
      in the completed phase 2/3 trial cohorts. If failed delta-subunit
      plasticity is the human lesion, GABRD genotype should modify the magnitude
      of response to delta-subunit-active neuroactive steroids; if the lesion is
      purely ligand withdrawal, it should not.
  evidence:
  - reference: PMID:18667149
    reference_title: "GABA(A)R plasticity during pregnancy: relevance to postpartum depression."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We suggest that Gabrd(+/-) and Gabrd(-/-) mice constitute a mouse model of
      postpartum depression that may be useful for evaluating potential
      therapeutic interventions.
    explanation: >-
      The authors present the plasticity-failure evidence explicitly as a mouse
      model, leaving human correspondence to be established.
- discussion_id: ppd_gabab_versus_gabaa_inhibitory_axis
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Loss of GABAergic Inhibitory Tone
  - genetic#KCTD16
  prompt: >-
    Postpartum depression risk shares a genome-wide significant locus with
    premenstrual disorder at KCTD16, an auxiliary subunit of the metabotropic
    GABA-B receptor, yet every mechanistic and therapeutic strand in this entry
    runs through the ionotropic GABA-A receptor. Does GABA-B signalling
    contribute to the loss of inhibitory tone in postpartum depression, or is
    the KCTD16 association acting through something other than the receptor
    complex its protein belongs to?
  rationale: >-
    The two claims are not in conflict, but nothing currently connects them.
    The curated chain is neurosteroid withdrawal acting on GABA-A receptors, and
    it is supported by the efficacy of two GABA-A positive allosteric
    modulators. Allopregnanolone has no comparable action at GABA-B receptors,
    so a genuine GABA-B contribution would have to be a parallel route to
    reduced inhibitory tone rather than a step in the neurosteroid pathway.
    Resolving this matters for two reasons. First, it determines whether the
    shared premenstrual-disorder and postpartum-depression liability is
    hormone-response machinery or general inhibitory tone, which is what makes
    the two disorders cross-inherited. Second, it is the difference between a
    treatment landscape confined to neuroactive steroids and one that includes
    GABA-B-directed agents. The evidence is currently thin on both sides: the
    locus is a single unreplicated preprint finding whose functional
    consequence for KCTD16 expression is unmeasured, and the KCTD16 to GABA-B
    link, while solid, comes from rodent brain proteomics with no postpartum
    context.
  proposed_experiments:
  - experiment_id: exp_ppd_kctd16_replication_and_expression
    name: Replication of the KCTD16 shared locus and its effect on KCTD16 expression
    description: >-
      Replicate the cross-trait premenstrual-disorder and postpartum-depression
      association at the KCTD16 3' UTR locus in an independent, ideally
      non-European-ancestry cohort, and determine the direction of effect on
      hippocampal KCTD16 expression. A peer-reviewed replication with a
      measured expression direction is the precondition for treating GABA-B
      signalling as a mechanism here rather than as an unexplained association.
  - experiment_id: exp_ppd_gabab_tone_in_withdrawal_model
    name: GABA-B contribution to inhibitory tone in a neurosteroid-withdrawal model
    description: >-
      In the pseudopregnancy or Gabrd model, test whether GABA-B receptor
      signalling changes across the peripartum transition independently of
      GABA-A subunit remodeling, and whether manipulating Kctd16 alters the
      postpartum depression-like phenotype. A phenotype that moves with Kctd16
      but not with GABA-A subunit composition would establish GABA-B as a
      parallel route to loss of inhibitory tone; no effect would argue the
      human locus acts elsewhere.
  evidence:
  - reference: PPR:PPR1293935
    reference_title: "Shared Genetic Architecture of Premenstrual Disorder and Postpartum Depression: Registry-Based and Genetic Evidence"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      locus implicates GABAB–mediated inhibitory signaling in both disorders
    explanation: >-
      States the GABA-B interpretation that this entry's GABA-A-centred
      mechanism does not currently accommodate.
  - reference: PPR:PPR1293935
    reference_title: "Shared Genetic Architecture of Premenstrual Disorder and Postpartum Depression: Registry-Based and Genetic Evidence"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The register-based heritability was 0.35 (95% CI: 0.29–0.41) for PMD and
      0.31 (95% CI: 0.23–0.37) for PPD, with a positive genetic correlation
      between these disorders
    explanation: >-
      Quantifies the shared heritable liability that the KCTD16 and PCDH9 loci
      are proposed to partly explain, establishing that there is a real
      cross-disorder signal to account for.
  - reference: PPR:PPR1293935
    reference_title: "Shared Genetic Architecture of Premenstrual Disorder and Postpartum Depression: Registry-Based and Genetic Evidence"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Beyond the lead loci, TWAS suggested that the shared risk variants may
      partially act through genetically regulated gene expression across brain,
      endocrine and immune-related tissues
    explanation: >-
      The authors themselves treat the mechanistic route as unsettled and
      distributed beyond the lead loci, which is why this is recorded as an
      open gap rather than as a curated mechanism.
notes: >-
  Curated in response to the obstetric coverage gap documented in
  monarch-initiative/dismech#7837, which identified postpartum depression as the
  most tractable missing obstetric entry: an existing MONDO anchor, a
  well-defined mechanism, and two approved mechanism-matched drugs.

  Terminology note: HP:0100602 (Preeclampsia) and several other pregnancy-related
  HPO terms sit outside the HP:0000118 phenotypic-abnormality root used by the
  PhenotypeTerm enum, as documented in #7837. This entry is unaffected because
  its phenotypes are general depressive-symptom terms that sit under Behavioral
  abnormality; the peripartum context is carried by the disease term rather than
  by phenotype qualifiers.

  The GABA-A receptor subunit-plasticity step is supported by mouse genetics
  rather than human tissue data; this is recorded as a HUMAN_MODEL_MISMATCH
  discussion rather than left implicit, since it is the one link in the
  canonical chain without direct human evidence.

  Deep research: a `claude_code` provider run was performed via
  `just research-disorder claude_code Postpartum_Depression`
  (research/Postpartum_Depression-deep-research-claude_code.md; 22 web searches,
  58 citations, 298 s). It corroborated the neurosteroid-withdrawal chain and
  the HPA/placental-CRH arm as curated, and surfaced one material correction:
  brexanolone had been withdrawn from the market, which this entry had not
  reflected. That lead was verified independently against the Federal Register
  notice before being curated, per the rule that DR outputs are leads rather
  than ground truth. Findings from the run NOT yet curated, and left as future
  work rather than added without verification: the postpartum inflammatory arm
  (IL-6/hs-CRP as predictors, kynurenine-pathway and NLRP3 activation), the
  limbic-prefrontal imaging signature (notably blunted rather than hyperreactive
  amygdala response, reported as distinguishing PPD from non-perinatal MDD), and
  oxytocin-signaling involvement.

  Shared genetic architecture with premenstrual disorder (KCTD16, PCDH9) was
  added from a medRxiv preprint, PPR:PPR1293935, per
  monarch-initiative/dismech#8479. Both loci are curated in `genetic:` as
  SUSCEPTIBILITY associations and deliberately not wired into the
  pathophysiology chain: the source is not peer reviewed and the loci are
  unreplicated, so the GABA-B reading of KCTD16 is recorded as the open
  ppd_gabab_versus_gabaa_inhibitory_axis gap instead of as mechanism. Neither
  locus is supported by the preprint alone — KCTD16's assignment to GABA-B
  signalling rests on Schwenk et al. 2010 (PMID:20400944), and PCDH9 is curated
  as a positional association with no mechanistic claim attached. The
  corresponding shared-locus entries have NOT been added to
  Premenstrual_Dysphoric_Disorder.yaml, whose `genetic:` section still uses the
  older free-text `association:` style; doing that symmetrically is follow-up
  work.
📚

References & Deep Research

Deep Research

1
Claude Code ▸
Postpartum Depression (PPD) — Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 58 citations 2026-08-02T09:59:25.034149

Postpartum Depression (PPD) — Comprehensive Research Report

1. Disease Information

Overview: Postpartum depression (PPD) is a non-psychotic, moderate-to-severe depressive episode that begins during pregnancy or within the weeks following childbirth. DSM-5 formally reclassified "postpartum depression" as major depressive disorder (MDD) with peripartum onset, defined as a major depressive episode with onset during pregnancy or within 4 weeks postpartum — a change made because roughly half of "postpartum" episodes actually begin antenatally. ICD-11 uses a broader 6-week postnatal onset window. Clinically and in most epidemiological literature, "postpartum depression" is used more loosely to include episodes beginning up to 12 months after delivery. PPD is distinguished from the much more common, self-limited "baby blues" (mild tearfulness/mood lability peaking days 3–5, resolving within ~2 weeks, occurring in up to 80% of mothers) and from postpartum psychosis (a psychiatric emergency with delusions/hallucinations, incidence ~0.1–0.2%, usually within the first 2 weeks postpartum).

Key identifiers: - MONDO: MONDO:0005929 - ICD-11 (MMS): 6E20.0 (Foundation ID 169328648) - ICD-10 / ICD-10-CM: F53 (Mental and behavioural disorders associated with the puerperium, not elsewhere classified); F53.0 (Postpartum depression, mild) - DSM-5: Major Depressive Disorder, with Peripartum Onset specifier (296.xx) - MeSH: D019052 (Depression, Postpartum) - No dedicated OMIM phenotype number exists — PPD is modeled as a complex/multifactorial trait, not a Mendelian disorder, and is typically discussed under MDD-related OMIM entries (e.g., PHIH loci) rather than its own OMIM MIM number. - Orphanet does not carry a distinct PPD entry (Orphanet does list postpartum psychosis as ORPHA:443173), consistent with PPD being a common complex psychiatric condition rather than a rare disease.

Synonyms: Postnatal depression; peripartum depression (DSM-5 term); puerperal depression; maternal postnatal depression. Note: "postpartum depression" is sometimes used loosely to include "perinatal depression" (antenatal + postnatal).

Evidence basis: Aggregated disease-level knowledge, drawn from large cohort studies (e.g., the French IGEDEPP cohort), meta-analyses across country-level EHR/registry data, and increasingly EHR-based case ascertainment algorithms validated within integrated health systems (e.g., PMC10018380 validated PPD identification in a large integrated US health system's EHR).

Sources: Postnatal mental disorder: towards ICD-11 (PMC), Postpartum depression: a disorder in search of a definition (PMC), Identification of Postpartum Depression in EHRs (PMC), DSM V Postpartum Depression Criteria, Postpartum psychosis (Orphanet)

2. Etiology

Causal framework: PPD is a multifactorial, biopsychosocial disorder — no single causal gene or lesion; rather a convergence of genetic susceptibility, the abrupt peripartum neuroendocrine/neurosteroid transition, immune/inflammatory shifts, and major psychosocial stressors of the postpartum period, occurring against a background of prior depression/anxiety vulnerability.

Genetic risk factors: - Heritability: Twin studies estimate PPD heritability at 38–54%, generally higher than heritability estimates for non-perinatal depression in the same cohorts (Treloar et al.: 38% PPD vs 25% non-perinatal; Viktorin et al.: 44–54% PPD vs 32% non-perinatal), with roughly a third of the genetic architecture unique to the perinatal phenotype rather than shared with general MDD. ("Heritability of Perinatal Depression and Genetic Overlap With Nonperinatal Depression," Am J Psychiatry, PMID search via psychiatryonline.org) - GWAS: The first large PPD GWAS meta-analysis (Guintivano et al. 2023, Am J Psychiatry, DOI 10.1176/appi.ajp.20230053) combined 18 European-ancestry cohorts (17,339 cases/53,426 controls) plus East Asian and African-ancestry cohorts (total 18,770 cases/58,461 controls). SNP-based heritability was ~14% of variance attributable to common variants. The lead (non-genome-wide-significant) SNP mapped to TXNRD2 (thioredoxin reductase 2, a mitochondrial redox/metabolism gene). Genetic correlations were significant with major depression, bipolar disorder, anxiety disorders, PTSD, insomnia, and polycystic ovary syndrome. - A 2024 GWAS (Li et al., Psychiatry and Clinical Neurosciences) identified 8 additional risk loci, and a separate 2023 medRxiv/PMC preprint reported a novel susceptibility locus at 18q12.1. - Candidate gene categories implicated across studies: estrogen-signaling genes, oxytocin pathway genes (OXTR, OXT), and GABAergic neurotransmission genes — echoing the neurosteroid/GABA-A mechanistic hypothesis (Section 6). - HGNC candidates for annotation: OXTR (HGNC:8529), TXNRD2 (HGNC:12437), TTC9B, HP1BP3 (epigenetic biomarker loci, see below).

Environmental / psychosocial risk factors (strong, consistently replicated): - Personal history of depression or anxiety (single strongest predictor) - Depression/anxiety during pregnancy (antenatal depression) - Poor sleep quality/short sleep duration in pregnancy (≤6 hours) - Low social support, poor partner relationship, intimate partner violence - Unplanned/unwanted pregnancy - Obstetric complications (preterm birth, cesarean delivery, negative birth experience), gestational diabetes - Low socioeconomic status, chronic stress, adverse life events - Excessive infant crying / difficult infant temperament, low maternal self-efficacy

Protective factors: - Strong partner and social support - Secure early mother-infant bonding (also buffers downstream child effects — see Section 11) - Regular moderate-intensity aerobic exercise during/after pregnancy - Adequate sleep - Psychosocial/psychoeducational prenatal interventions (peer support, structured counseling) - No specific protective genetic variant has been robustly identified to date (an evidence gap).

Gene–environment interaction: The dominant mechanistic GxE model is the hormone-sensitivity hypothesis: it is not absolute hormone levels but differential sensitivity to the hormonal (estrogen/progesterone/allopregnanolone) fluctuation that confers risk, and this sensitivity appears to have an epigenetic/genetic substrate (estrogen-responsive DNA methylation at HP1BP3/TTC9B; see Section 4). Stressful life events interact with genetic loading for depression risk (studied e.g. in NCT01648816, "Interaction Between Genetic Factors and Maternal Stressors During Pregnancy").

Sources: First Large GWAS Meta-Analysis for PPD (AJP), Meta-Analyses of GWAS for PPD (AJP full text), MGH Women's Mental Health summary of GWAS, Novel susceptibility locus 18q12.1 (medRxiv), Heritability of Perinatal Depression (AJP), Psychiatric Risk Factors for PPD: Systematic Review (PMC), Risk factors community-based study

3. Phenotypes

PPD phenotypes span symptoms/behavioral changes (core, per DSM-5 MDE criteria applied in the peripartum window) and laboratory/biomarker abnormalities (research-stage, not yet diagnostic).

Core symptom/behavioral phenotypes (DSM-5 MDE criteria, ≥5 of 9, ≥2 weeks, most of the day nearly every day)

Phenotype Suggested HPO term Notes
Depressed mood HP:0000716 (Depressivity) Core symptom
Anhedonia / loss of interest HP:0031966 (Anhedonia) or HP:0000716
Appetite disturbance (increase or decrease) HP:0004396 (Decreased body weight) / HP:0004324 (Weight gain)
Sleep disturbance (insomnia/hypersomnia) HP:0100785 (Insomnia) Distinct from normal infant-care sleep disruption
Psychomotor agitation or retardation HP:0025278 (Psychomotor agitation)
Fatigue / loss of energy HP:0012378 (Fatigue)
Difficulty concentrating / indecisiveness HP:0031936 (Decreased ability to concentrate)
Feelings of worthlessness / excessive guilt HP:0031332 (approx.; guilt not separately coded in HPO — free text) PPD-specific: guilt over perceived maternal inadequacy
Suicidal ideation HP:0031589 (Suicidal ideation)
Anxiety (very frequent comorbid) HP:0000739 (Anxiety) Present in most PPD presentations
Irritability / hostility toward infant HP:0000737 (Irritability) Characteristic PPD-specific presentation
Intrusive/obsessive worry about infant harm (behavioral, no direct HPO) Distinguish from psychotic infanticidal ideation
Impaired mother-infant bonding (behavioral phenotype, no direct HPO) ~57% of PPD inpatients show impaired bonding at admission

Onset: Peak onset 4–12 weeks postpartum by DSM-5/clinical convention, though ~50% of "postpartum" episodes have antenatal onset (hence DSM-5's "peripartum" reframing). Severity: Ranges mild to severe, including psychotic features in a minority; assessed via HAM-D-17 or EPDS score bands. Progression/course: Typically episodic; most cases remit within 3–6 months with treatment, but ~30–50% have a chronic or recurrent course if untreated, and prior PPD strongly predicts recurrence in subsequent pregnancies (30–50% recurrence risk). Frequency among affected individuals: Global pooled prevalence of depressive symptoms ~19% (see Section 9); frequency of individual symptom domains within diagnosed PPD populations less systematically quantified in registries (an evidence gap best filled via cohort-specific data, e.g., IGEDEPP network-analysis paper). QoL impact: Impaired maternal functioning, impaired bonding (57.1% impaired at admission, dropping to 18.2% by discharge with treatment), and downstream child cognitive/behavioral/attachment effects (see Section 11).

Sources: Perinatal Depression - StatPearls, Major depressive episode and PPD network analysis (IGEDEPP, PMC), Maternal Attachment Networks and Bonding Disturbances (PMC)

4. Genetic / Molecular Information

  • No single causal gene — PPD is polygenic/complex, unlike Mendelian OMIM disorders.
  • GWAS-implicated loci: lead signal near TXNRD2 (thioredoxin reductase 2; mitochondrial antioxidant/redox enzyme) in the 2023 AJP meta-analysis (no locus reached genome-wide significance in the European-only analysis); additional loci reported in the 2024 Li et al. study (8 loci) and an 18q12.1 locus (2023 preprint).
  • Variant classification: Common variants of small individual effect (polygenic architecture), not ACMG-classified pathogenic/likely-pathogenic variants — PPD is not curated in ClinVar as a Mendelian phenotype.
  • Population frequency: Not applicable in the Mendelian sense; SNP-based heritability (h²SNP) ≈ 14%.
  • Somatic vs. germline: Germline (heritable common-variant) architecture; no somatic component described.
  • Functional consequence themes: GWAS/candidate-gene results converge on (1) estrogen receptor signaling, (2) oxytocin signaling (OXTR/OXT), (3) GABAergic neurotransmission, (4) mitochondrial/metabolic genes (TXNRD2), consistent with the neurosteroid-withdrawal and immune mechanistic models below.

Epigenetic information (a major PPD-specific research thread): - Prospective, prediction-oriented DNA methylation biomarker studies (Guintivano, Mehta, Kaminsky et al.) identified two blood-based methylation loci — HP1BP3 and TTC9B — measured antenatally, that predicted subsequent PPD with AUC = 0.87 in a discovery cohort of euthymic pregnant women, later independently replicated with variation tied to circulating hormone levels ("Replication of Epigenetic Postpartum Depression Biomarkers and Variation with Hormone Levels," Neuropsychopharmacology). - Methylation at these loci is estrogen-responsive: PPD-risk-associated methylation change correlates significantly with estrogen-induced methylation change in hippocampal tissue (rodent), supporting an "estrogen-sensitivity" mechanistic model in which the brains of at-risk women show exaggerated epigenetic reprogramming in response to the massive third-trimester rise and postpartum collapse of estradiol. - Bioinformatic annotation suggests HP1BP3 and TTC9B may be involved in synaptic plasticity; both have direct ties to estrogen signaling pathways. - Genome-wide blood gene-expression profiling (2021, Translational Psychiatry) found PPD-associated transcriptomic changes pointing to an altered immune landscape (71 genes significant at 2 months postpartum, FDR 5%), and separately, transcript-level enrichment for estrogen receptor signaling genes in early antenatal blood, confirming increased estrogen-signaling sensitivity as a biomarker axis even though plasma estradiol itself is not elevated in PPD cases relative to controls.

Chromosomal abnormalities: None specifically implicated; not a chromosomal/CNV disorder.

Suggested ontology terms for curation: HGNC gene symbols OXTR (hgnc:8529), TXNRD2 (hgnc:12437); GO biological process terms for "estrogen receptor signaling pathway" (GO:0030520) and "regulation of GABA-A receptor activity"; CHEBI terms for allopregnanolone (CHEBI:2755) and estradiol (CHEBI:16469).

Sources: Meta-Analyses of GWAS for PPD (AJP), Early predictive biomarkers — estrogen receptor signaling (PubMed), Seeing the Future: Epigenetic Biomarkers of PPD (PMC), Antenatal prediction of PPD with blood DNA methylation biomarkers (Mol Psychiatry), Replication of Epigenetic PPD Biomarkers (Neuropsychopharmacology), Genome-wide gene expression changes in PPD — altered immune landscape (Transl Psychiatry)

5. Environmental Information

  • Environmental/toxicant factors: No specific toxin or pollutant is established as a primary PPD cause; the dominant "environmental" contributors are psychosocial/physiological rather than toxicological.
  • Lifestyle factors: Poor/short sleep, sedentary behavior (exercise is protective — see Section 13), tobacco/alcohol use are associated with elevated risk in observational cohorts; low socioeconomic status and food/housing insecurity are consistently reported risk amplifiers.
  • Major life-event/stress exposures: Intimate partner violence, chronic relationship conflict, unplanned pregnancy, traumatic or medically complicated birth experience, lack of social support network.
  • COVID-19 pandemic as an environmental stressor exemplar: Pooled PPD prevalence rose to ~34% during the pandemic (roughly double pre-pandemic estimates), illustrating the sensitivity of PPD incidence to acute large-scale environmental/psychosocial stress.
  • Infectious agents: Not a primary etiologic category for PPD; postpartum thyroiditis (autoimmune, not infectious) is a relevant differential/comorbid endocrine condition (Section 10) but is not itself infectious.

Sources: Mapping global prevalence of depression among postpartum women (Transl Psychiatry), Postpartum depression statistics 2024

6. Mechanism / Pathophysiology

PPD pathophysiology converges on three interacting, partially causal-chain mechanisms: (A) neurosteroid/GABAergic withdrawal, (B) HPA-axis dysregulation and postpartum immune/inflammatory shift, and (C) altered emotion-circuit (limbic-prefrontal) function, with genetic/epigenetic estrogen-sensitivity as an upstream modifier of (A).

A. Neurosteroid (allopregnanolone) withdrawal — GABA-A mechanism (the best-established, drug-actionable pathway)

  • Causal chain: Massive third-trimester rise in progesterone and its neuroactive metabolite allopregnanolone (ALLO), a potent positive allosteric modulator of the GABA-A receptor → chronic ALLO exposure drives compensatory downregulation/altered subunit composition of GABA-A receptors (notably δ-subunit-containing extrasynaptic receptors) → parturition causes an abrupt, precipitous drop in ALLO ("neurosteroid withdrawal") → in women/mice whose GABA-A receptors fail to appropriately re-adapt (fail to upregulate δ-subunit-containing receptors as ALLO falls), there is a net loss of inhibitory tone → depressive-like and anxiety-like behavior, plus abnormal maternal behavior.
  • Model organism evidence: GABA-A receptor δ-subunit knockout mice fail to appropriately regulate receptor dynamics across the ALLO rise-and-fall of pregnancy/postpartum and display depression-like and anxiety-like behavior specifically in the postpartum period, plus abnormal maternal behavior with increased pup mortality (cannibalism/neglect) — phenotypes reversible by exogenous ALLO administration (Maguire & Mody, Neuron 2008, foundational paper; PMC12076219 extends this to a hypothalamic MPA–PVN circuit modulating postpartum depressive-like behavior).
  • Therapeutic translation: This mechanism directly motivated brexanolone (IV allopregnanolone analog; FDA-approved 2019 as Zulresso, first drug ever approved specifically for PPD; approval withdrawn April 2025 at manufacturer's request due to the burdensome 60-hour inpatient IV infusion protocol and >$34,000 cost) and zuranolone (oral synthetic neurosteroid GABA-A positive allosteric modulator, FDA-approved August 2023 as Zurzuvae) — see Section 12.

B. HPA axis dysregulation and postpartum inflammatory shift

  • Causal chain: Placental CRH secretion during pregnancy escapes normal cortisol negative feedback → abrupt post-delivery loss of placental CRH plus normal HPA recalibration creates a period of HPA-axis instability → proinflammatory cytokines (which are normally suppressed in the anti-inflammatory pregnancy state to protect the fetal allograft) rebound sharply after delivery in response to the physical trauma of childbirth (a "pro-inflammatory shift") → elevated IL-6 and hs-CRP postpartum are independent predictors of subsequent depression; PPD patients show decreased T-cell activation, increased proinflammatory cytokine secretion, kynurenine-pathway activation, and NLRP3 inflammasome activation.
  • Downstream neuroinflammatory link: Kynurenine pathway activation shunts tryptophan away from serotonin synthesis toward neurotoxic kynurenine metabolites, linking peripheral inflammation to central monoaminergic and glutamatergic dysfunction.

C. Emotion-circuit (limbic-prefrontal) dysfunction — neuroimaging correlates

  • Structural/functional MRI meta-analyses consistently implicate the medial prefrontal cortex (default-mode-network hub), anterior cingulate cortex, amygdala, and hippocampus.
  • Amygdala responses to negative emotional stimuli are typically blunted in PPD (contrasting with the hyperreactive amygdala more typical of non-perinatal MDD), suggesting a distinct PPD neurobiological signature.
  • Functional connectivity between the posterior cingulate cortex and right amygdala is disrupted; dorsolateral prefrontal cortex resting activity (fALFF) correlates negatively with depression severity.
  • Acupuncture intervention studies report partial normalization of amygdala subregion structure/function alongside symptom improvement, offered as indirect mechanistic/therapeutic-response evidence.

D. Oxytocin and estrogen/progesterone withdrawal (hormone-sensitivity hypothesis)

  • Estrogen surges ~100–1000-fold in the third trimester then collapses below pre-pregnancy levels within days of delivery ("estrogen withdrawal"); the hormone-sensitivity hypothesis (Bloch, Schmidt et al.) — supported by a landmark hormone-manipulation experimental paradigm — shows that experimentally induced supraphysiologic estradiol/progesterone followed by simulated "withdrawal" precipitates depressive symptoms selectively in women with a prior PPD history, even though absolute hormone trajectories do not differ from unaffected women; this is the direct human-experimental analog of the epigenetic estrogen-sensitivity biomarker findings in Section 4.
  • Estrogen withdrawal alters oxytocin signaling in the paraventricular hypothalamus and dorsal raphe nucleus, increasing postpartum anxiety in rodent models — mechanistically linking the hormone-withdrawal and neuroendocrine-behavioral axes.
  • Progesterone modulates oxytocin receptor sensitivity, providing a further node connecting the neurosteroid and oxytocin mechanisms.

Suggested GO/CL/UBERON terms

  • GO:0007165 (signal transduction) / GO:0030520 (estrogen receptor signaling pathway) / GO:0007214 (gamma-aminobutyric acid signaling pathway) / GO:0006954 (inflammatory response) / GO:0033197 (response to vitamin E — not relevant, omit) / GO:0034612 (response to tumor necrosis factor)
  • CL:0000617 (GABAergic neuron), CL:0000704 (astrocyte, for neuroinflammatory glial component), CL:0000542 (lymphocyte, for peripheral immune component)
  • UBERON:0001876 (amygdala), UBERON:0002771 (anterior cingulate cortex), UBERON:0002795 (mPFC region), UBERON:0002421 (hippocampal formation), UBERON:0035054 (hypothalamic paraventricular nucleus)

Sources: Allopregnanolone in Postpartum Depression (PMC), Allopregnanolone in PPD: Role in pathophysiology and treatment (PubMed), A Mouse Model of Postpartum Depression (MGH), Hypothalamic MPA-PVN Circuit in PPD Mouse Model (PMC), Inflammatory pathophysiological mechanisms in PPD (PMC), Elevated Hs-CRP and IL-6 after delivery (ScienceDirect), Neuroimaging biomarkers structural/functional/metabolic review (PMC), Consistent functional abnormalities in PPD, Estrogen withdrawal alters oxytocin signaling (bioRxiv), Pathophysiological Mechanisms Implicated in PPD (PMC)

7. Anatomical Structures Affected

  • Organ level: Primary organ = brain (CNS); no direct primary pathology in peripheral organs, though the postpartum uterus/placenta is the physiologic trigger organ (abrupt loss of placental steroidogenesis and CRH source at delivery). Endocrine system (HPA axis, ovarian/placental steroid axis, thyroid — postpartum thyroiditis is a relevant comorbid/differential endocrine condition) and immune system (postpartum pro-inflammatory shift) are secondarily involved. Body systems: nervous, endocrine, immune.
  • Tissue/cell level: Cortical and limbic neuronal populations (GABAergic interneurons expressing δ-subunit GABA-A receptors; glutamatergic pyramidal neurons in mPFC/hippocampus); astrocytes and microglia (neuroinflammatory component); circulating peripheral blood mononuclear cells / T cells and monocytes (peripheral inflammatory/immune signature used in blood-based biomarker studies).
  • Subcellular level: GABA-A receptor complex (plasma membrane, extrasynaptic and synaptic pools); mitochondria (TXNRD2 mitochondrial redox function implicated by GWAS); nuclear chromatin (DNA methylation changes at HP1BP3/TTC9B).
  • Localization (UBERON): Amygdala (UBERON:0001876), medial prefrontal cortex, anterior cingulate cortex (UBERON:0002771), hippocampus (UBERON:0002421), hypothalamic paraventricular nucleus, dorsal raphe nucleus (UBERON:0002043).
  • Lateralization: Not strongly lateralized; some studies report a left-dorsolateral-PFC correlation with symptom severity, but this is not a defining feature.

Sources: as in Section 6 (neuroimaging review references)

8. Temporal Development

  • Onset: By DSM-5, within pregnancy or the first 4 weeks postpartum ("peripartum onset" specifier); by broader clinical/epidemiological convention up to 12 months postpartum. Onset pattern is typically subacute (days to weeks), distinguishing it from the acute (within days), self-limited "baby blues" and from postpartum psychosis (acute onset, typically within the first 2 weeks, often days).
  • Progression/course: Most commonly episodic and treatable; the majority of women show significant improvement within 3–6 months of treatment initiation. Untreated or under-treated PPD can become chronic, blending into ongoing MDD beyond the first postpartum year.
  • Disease course pattern: Not classically relapsing-remitting like an autoimmune disease, but recurrence risk in future pregnancies is substantial (historically cited at 30–50% for women with a prior PPD episode — a widely used clinical estimate, though exact modern PMID-sourced recurrence rate should be separately verified for KB citation).
  • Remission: Both spontaneous (untreated, especially milder cases) and treatment-induced remission occur; treatment (SSRIs, psychotherapy, neurosteroid therapy) accelerates and increases likelihood of remission. Bonding-impairment data show striking within-admission improvement (57.1% → 18.2% impaired bonding from admission to discharge with treatment), illustrating a favorable short-term trajectory when treated.
  • Critical/vulnerability window: The first days to weeks postpartum represent the critical neuroendocrine vulnerability window (precipitous ALLO/estrogen withdrawal); this window is also the target for pre-emptive screening and rapid-acting neurosteroid intervention (zuranolone shows separation from placebo by Day 3 of a 14-day course).

Sources: SKYLARK trial results (MGH summary), Postpartum blues (background)

9. Inheritance and Population

Epidemiology: - Global pooled prevalence: A 2023 meta-analysis spanning 412 studies across 46 countries estimated a global pooled prevalence of 19.18% (95% CI 18.02–20.34%), with national estimates ranging from ~3% to 44%. WHO cites a broad range of 10–20% worldwide. - Regional variation: ~15.5% in high-income countries vs. ~19.9% in developing regions (2021 estimates); highest reported regional rate Southern Africa (~39.96%); country-level extremes reported at Denmark ~6.48% (lowest) and Afghanistan ~61% (highest) in some analyses. - US trend: Reported PPD prevalence rose from 9.4% (2010) to 19.0% (2021), partly reflecting improved screening/detection as well as true risk-factor shifts. By race/ethnicity in the same US data: ~21% White, ~19% Hispanic, ~22% Black, ~14% Asian/Pacific Islander women reporting PPD symptoms. - Pandemic effect: Pooled PPD prevalence during COVID-19 rose to ~34%, roughly double pre-pandemic estimates, underscoring the psychosocial-stress sensitivity of the disorder. - Underdiagnosis: Up to ~50% of PPD cases are estimated to go undiagnosed/untreated in various settings.

Genetic architecture / inheritance pattern: Complex/multifactorial (polygenic) — not Mendelian. No AD/AR/X-linked pattern; no established penetrance, expressivity, anticipation, mosaicism, founder-effect, or carrier-frequency concepts apply in the classical single-gene sense. SNP-based heritability ≈14% (common variants); twin-study broad-sense heritability 38–54% (see Section 2/4).

Population demographics: - Sex: By definition affects only birthing individuals (female-specific/perinatal condition); "sex ratio" concept not applicable in the traditional sense, though partner (paternal) postpartum depression is a related, distinct phenomenon in the perinatal-mental-health literature (not covered here). - Age distribution: Can occur at any reproductive age; younger maternal age and adolescent/teenage motherhood are reported as risk-elevating in some meta-analyses (see psychosocial-intervention-in-teenage-mothers meta-analysis). - Geographic distribution: Highly variable by country/region as above; disparities strongly track socioeconomic and healthcare-access factors as well as cultural stigma affecting reporting/screening uptake. - Ethnic/racial disparities: Documented disparities in US data (higher self-reported rates among Black and White women vs. Asian/Pacific Islander women), with a 2023 AJP paper specifically examining "Adversity and Resilience, Postpartum Depression, Suicide, and Racial/Ethnic Disparities."

Sources: Postpartum depression statistics 2024 (SingleCare), Mapping global prevalence of depression among postpartum women (Transl Psychiatry), Exploring predictors and prevalence of PPD: Multinational study (PMC), Adversity/Resilience/Racial Disparities (AJP)

10. Diagnostics

Clinical criteria: DSM-5 MDE criteria applied with the "peripartum onset" specifier (pregnancy through 4 weeks postpartum); ICD-11 6E20.0 uses a 6-week window. No dedicated PPD-specific diagnostic algorithm exists outside standard MDE criteria — diagnosis is fundamentally clinical.

Screening instruments (not diagnostic, but central to case detection): - Edinburgh Postnatal Depression Scale (EPDS): 10-item, perinatal-period-specific self-report instrument that also captures 2 anxiety items; free, validated, translated into many languages, widely used as the primary perinatal screening tool globally. - PHQ-9: Also validated for the perinatal population, self-administered, free. - Screening policy variation: US-based organizations (e.g., Postpartum Support International/PSI) recommend universal screening using EPDS or PHQ-9 at multiple perinatal touchpoints. By contrast, UK NICE guidance recommends the 2 Whooley questions with EPDS as an adjunct, and does not endorse universal formal-scale screening — an internationally divergent policy area worth flagging (a genuine cross-jurisdictional guideline discrepancy rather than a single consensus).

Laboratory/biomarker tests (research-stage, not yet standard-of-care diagnostics): - Antenatal DNA methylation panel at HP1BP3/TTC9B loci (AUC 0.87 in the discovery cohort) — a promising predictive (not diagnostic) blood biomarker, not yet in routine clinical use. - Elevated IL-6 and hs-CRP postpartum as candidate inflammatory biomarkers/predictors. - Thyroid function testing (TSH, thyroid antibodies) is clinically indicated to rule out postpartum thyroiditis, an important differential/comorbid diagnosis that can mimic or exacerbate mood symptoms.

Differential diagnosis: - Baby blues (postpartum blues): milder, self-limited, resolves within 2 weeks, does not significantly impair function — distinguished by duration/severity, not distinct pathophysiology. - Postpartum psychosis: psychiatric emergency; delusions, hallucinations, agitation, insomnia, cognitive impairment, incidence ~0.1–0.2% of new mothers, often no prior psychiatric history, onset typically within first 2 weeks — requires urgent inpatient management, distinct from PPD though sometimes preceded by mood symptoms. - Postpartum thyroiditis: autoimmune thyroid dysfunction in the postpartum period can produce depressive (hypothyroid phase) or anxious/hypomanic-like (hyperthyroid phase) symptoms and has been specifically implicated as a contributor to or mimic of postpartum psychosis in case literature — thyroid panel is a standard part of the diagnostic workup to exclude this mimicker. - Substance-induced mood disorder, bipolar disorder with peripartum episode (important to screen for bipolarity before prescribing antidepressant monotherapy), and adjustment disorder.

Genetic testing: Not clinically indicated (no Mendelian gene panel exists); this is a research-only domain (GWAS/methylation biomarker development, not diagnostic gene panels, WES/WGS, CMA, karyotyping, or repeat-expansion testing).

Sources: EPDS / screening recommendations (PSI), Universal Screening for Maternal Mental Health Disorders, Postpartum Psychosis as Consequence of Thyroiditis vs Relapse (PMC), Postpartum Mood Disorders and Thyroid Autoimmunity (PMC), Thirty years with the EPDS (Br J Psychiatry)

11. Outcome / Prognosis

  • Mortality: PPD is a major contributor to maternal suicide, one of the leading causes of pregnancy-associated death in the first postpartum year in several high-income-country surveillance systems (an important, separately-citable statistic for KB curation — the 2023 AJP paper on adversity/resilience/PPD/suicide/racial disparities is directly relevant here and should be pulled for exact figures during curation).
  • Recovery/treatment response: Prognosis is generally favorable with treatment — most women achieve significant symptom improvement within weeks to months; zuranolone and brexanolone trials demonstrate rapid response (symptom separation from placebo by Day 3 of a 14-day oral course), and standard antidepressant/psychotherapy approaches show good response rates over 6–12 weeks.
  • Impact on mother-infant bonding (a key functional-outcome domain): 57.1% of hospitalized PPD patients show impaired bonding at admission, improving to 18.2% impaired at discharge — indicating bonding impairment is common but substantially reversible with treatment.
  • Child developmental outcomes: Untreated PPD is associated with insecure infant attachment, and downstream child behavioral/cognitive/emotional difficulties; a 2025 longitudinal study found mother-to-infant bonding mediates 34.6% of the effect of postpartum maternal depression on child difficulties, and secure early bonding partially buffers the long-term (school-age) effects of PPD on child outcomes — establishing bonding quality as both an outcome and an effect-modifier/mediator.
  • Recurrence: Elevated risk of recurrence in subsequent pregnancies and of transition to chronic/recurrent MDD if untreated (see Section 8).
  • Prognostic factors: Symptom severity at presentation, presence of prior depression/anxiety history, quality of social/partner support, timeliness of treatment initiation, and (per newer research) inflammatory/epigenetic biomarker profiles are candidate prognostic indicators, though none are yet clinically validated prognostic tools.

Sources: Mother-infant bonding can buffer long-term effects of PPD on child outcomes, Maternal Attachment Networks and Bonding Disturbances (PMC), PPD and bonding: long-term effects on school-age children (ScienceDaily), Adversity and Resilience, PPD, Suicide, and Racial/Ethnic Disparities (AJP)

12. Treatment

Pharmacotherapy — Neurosteroid/GABA-A modulators (PPD-specific, mechanism-targeted; NCIT:C15986 Pharmacotherapy): - Brexanolone (Zulresso): IV allopregnanolone analog, FDA-approved 2019 as the first drug specifically approved for PPD; 60-hour continuous inpatient infusion; FDA approval withdrawn April 14, 2025 at manufacturer request due to cost (>$34,000/patient) and complex administration logistics. - Zuranolone (Zurzuvae): Oral synthetic neurosteroid, GABA-A receptor positive allosteric modulator engineered to overcome allopregnanolone's poor oral bioavailability/short half-life; FDA-approved August 2023, 14-day oral course, 50 mg daily. SKYLARK Phase 3 trial (NCT04442503): LS-mean HAM-D-17 change from baseline at Day 15 = −15.6 (zuranolone) vs −11.6 (placebo), difference −4.0 points (p=0.0007); improvement detectable as early as Day 3 (mean HAM-D reduction 9.5 vs 6.1, p=0.0008), sustained through Day 45. Also improves insomnia symptoms specifically. Currently the only FDA-approved oral, at-home PPD-specific pharmacotherapy.

Pharmacotherapy — Standard antidepressants: - SSRIs are first-line per ACOG (2023 Clinical Practice Guideline No. 5): sertraline or escitalopram preferred, especially in treatment-naive patients (favorable lactation safety profile is a key selection driver, though not itself a mechanistic point). - Standard antidepressant classes (SNRIs, etc.) used as in general MDD when SSRIs are ineffective/not tolerated.

Psychotherapy (first-line for mild-moderate PPD, per multiple guideline summaries): - Cognitive Behavioral Therapy (CBT): structured, time-limited, targets negative thought patterns/behaviors. - Interpersonal Psychotherapy (IPT): targets role transition and interpersonal relationship strain specific to new motherhood; demonstrated efficacy including in low- and middle-income country settings. - Psychoeducation and structured digital/web-based interventions (e.g., MomMoodBooster) also show efficacy.

Supportive/behavioral care: - Peer support programs, structured social support interventions, sleep optimization.

Experimental / emerging: - Additional neuroactive-steroid compounds and next-generation GABA-A modulators in clinical development (ongoing trials registered at ClinicalTrials.gov). - Novel psychotherapeutic delivery models under trial (e.g., NCT06991166 "OBWELL").

Treatment outcomes / adverse events: - Zuranolone: generally well tolerated; somnolence/sedation is the most common adverse effect (mechanistically expected from GABA-A potentiation); real-world pharmacovigilance analyses (FAERS-based) are ongoing to characterize post-marketing safety. - Brexanolone: sedation, loss of consciousness risk (boxed warning), requiring continuous monitoring during the 60-hour infusion — a major driver of its subsequent market withdrawal.

Suggested NCIT terms: NCIT:C15986 (Pharmacotherapy) as treatment_term, with therapeutic_agent bound to CHEBI/NCIT terms for zuranolone and sertraline; therapeutic_modality: SMALL_MOLECULE for both; brexanolone/zuranolone could additionally be flagged as neurosteroid GABA-A PAMs distinct from classical antidepressants, aligning with the general NCIT:C49236 (Therapeutic Procedure) / psychotherapy-specific NCIT codes (e.g., a Cognitive/Interpersonal Therapy NCIT term) for CBT/IPT.

Sources: ACOG Clinical Practice Guideline No. 5, Neurosteroids and PPD: Mechanism, Efficacy, Approval of Brexanolone and Zurzuvae (PMC), Zuranolone and Brexanolone for Treatment of PPD (Obstet Gynecol), SKYLARK study primary/secondary endpoints (Biogen press release), Post-marketing safety of zuranolone (FAERS analysis, PMC), Current Developments: Zuranolone (PMC)

13. Prevention

  • Primary prevention:
  • Aerobic exercise: Network meta-analysis of 26 RCTs (n=2,867) found moderate-intensity aerobic exercise (3–4×/week, 35–45 min) significantly reduced depressive symptoms vs. standard care (MD = −1.90, 95% CI −2.58 to −1.21); supervised and team-based exercise slightly outperformed unsupervised/individual exercise.
  • Psychosocial/psychoeducational interventions: Meta-analytic pooled effect size −0.5 (95% CI −0.95 to −0.06) for prevention of PPD at final assessment; interventions include peer support, structured counseling, educational programs, CBT-based prevention, motivational interviewing, and mindfulness-based programs. Specifically effective in high-risk subgroups (e.g., adolescent/teenage mothers per a dedicated systematic review/meta-analysis of RCTs).
  • App-based/digital interventions: Systematic review/meta-analysis supports modest preventive efficacy of app-based interventions.
  • Secondary prevention (screening for early detection): Universal EPDS/PHQ-9 screening at perinatal touchpoints (endorsed by PSI/ACOG in the US), though international guideline divergence exists (NICE in the UK does not endorse universal formal-scale screening — see Section 10).
  • Targeted/risk-stratified prevention: Women with personal/family history of depression, prior PPD, or other identified risk factors (Section 2) are candidates for targeted surveillance and pre-emptive psychosocial support; the antenatal DNA methylation biomarker panel (Section 4) is a research-stage tool aimed at enabling this kind of risk stratification.
  • Tertiary prevention: Early treatment to prevent chronicity, recurrence in future pregnancies, and downstream child developmental harms (mediated substantially through bonding — Section 11); relapse-prevention planning for women with prior PPD episodes, given elevated recurrence risk in subsequent pregnancies.
  • Counseling: Preconception/prenatal counseling on recurrence risk for women with a prior PPD history is standard clinical practice (parallel to genetic counseling in Mendelian disease, though here it addresses recurrence-risk counseling rather than inheritance-risk counseling).
  • Immunization: Not applicable (non-infectious).

Sources: Effectiveness of aerobic exercise (Meta-analysis/network meta-analysis, PLOS One), Physical exercise interventions for perinatal depression (Frontiers), Effectiveness of Psychosocial Interventions Preventing PPD Among Teenage Mothers (PMC), The preventive effect of psychological/psychosocial interventions on PPD (ScienceDirect), App-based interventions for prevention of PPD (PMC)

14. Other Species / Natural Disease

  • PPD as clinically defined is a human-specific diagnostic construct (tied to DSM-5/ICD-11 criteria); a directly analogous naturally occurring veterinary disease entity is not established in the literature surveyed. No OMIA (Online Mendelian Inheritance in Animals) entry or veterinary case-series literature on naturally occurring "postpartum depression" in companion animals or livestock was found in this search — this appears to be a genuine gap rather than an oversight, since postpartum affective states in animals are typically studied only as experimentally induced models (Section 15) rather than documented spontaneous veterinary disease.
  • Comparative/evolutionary biology: The core neuroendocrine substrate (progesterone/allopregnanolone rise-and-fall around parturition, GABA-A receptor plasticity, oxytocin-mediated maternal behavior circuitry) is deeply conserved across mammals, which is precisely why rodent models are considered mechanistically informative despite the absence of a documented "natural" PPD phenotype in non-human species; abnormal maternal behavior with increased offspring mortality (neglect/cannibalism) in genetically or pharmacologically manipulated rodents is the closest cross-species analog to human PPD's impact on maternal-infant bonding.
  • Taxonomy: Primary study species is Mus musculus (NCBITaxon:10090) and Rattus norvegicus (NCBITaxon:10116); no specific affected breed/strain beyond the genetically selected WKY/WMI depression-model rat line and various targeted knockout mouse lines (Section 15).

Sources: (absence of positive hits is itself informative) Postpartum depression spans generations, animal study suggests (ScienceDaily)

15. Model Organisms

Genetic (knockout) mouse models — the mechanistic gold standard: - GABA-A receptor δ-subunit knockout mice (Maguire & Mody, Neuron 2008; foundational model): fail to appropriately regulate GABA-A receptor subunit composition across the pregnancy-to-postpartum allopregnanolone rise-and-fall, and display depression-like and anxiety-like behavior specific to the postpartum period, plus abnormal maternal behavior and increased pup mortality (neglect/cannibalism) — phenotypes rescued by exogenous allopregnanolone administration. This model directly recapitulates the human neurosteroid-withdrawal hypothesis and provided the preclinical rationale for brexanolone/zuranolone development. - Follow-on circuit-level work: a hypothalamic medial preoptic area (MPA)–paraventricular nucleus (PVN) circuit has been shown to modulate depressive-like behaviors in a mouse PPD model (2024/2025 PMC12076219), extending the mechanism from receptor-level to defined neural-circuit level.

Induced (stress/hormone-manipulation) rodent models: - Maternal separation model: dams separated from litters (e.g., 3 hr/day, lactation days 2–12) → poor maternal care, transient offspring anxiety. - Chronic stress models: chronic social stress or chronic restraint stress during pregnancy/postpartum → increased depressive-like and aggressive maternal behavior, altered maternal care toward pups; a transgenerational rat study (Tufts Cummings School) showed early-life chronic social stress effects propagate across generations of maternal behavior/physiology. - Corticosterone-treatment model: postpartum CORT administration (e.g., 40 mg/kg daily) in Sprague-Dawley dams to model HPA-axis-driven depressive phenotypes; shown to impair maternal care and produce neurochemical alterations in dams plus long-lasting sociability impairment in offspring. - Genetic selectively-bred model: the Wistar Kyoto More Immobile (WMI) rat strain, bidirectionally selectively bred from the parental WKY line for depression-like immobility behavior, used to study postpartum-specific hypothalamic gene expression and behavior.

Phenotype recapitulation and limitations: - Rodent models robustly recapitulate core depression-like behavioral readouts (forced-swim/tail-suspension immobility, anhedonia proxies), impaired maternal care, and the neurosteroid/GABA-A mechanistic axis, and have directly enabled a first-in-class drug class (neurosteroid GABA-A PAMs). - Limitations: rodent "depression-like behavior" readouts are behavioral proxies rather than validated homologs of human subjective mood/cognitive symptoms (rumination, guilt, suicidal ideation have no clean rodent correlate); psychosocial risk factors central to human PPD (relationship stress, cultural/socioeconomic stigma, sleep deprivation from infant care specifically) are harder to model with construct validity; and the translational gap between rodent HPA/immune findings and the specific human postpartum immune-shift literature (Section 6B) is not fully resolved.

Resources: MGI (Mouse Genome Informatics) for GABA-A δ-subunit knockout lines; standard rodent behavioral-neuroscience repositories for the WMI rat strain and induced-stress protocols.

Sources: A Mouse Model of Postpartum Depression (MGH), Hypothalamic MPA-PVN Circuit Modulates Depressive-Like Behaviors in PPD Mouse Model (PMC), Modeling postpartum depression in rats: theoretic and methodological issues, Hypothalamic Gene Expression and Postpartum Behavior in a Genetic Rat Model of Depression (PMC), PPD in rats causes poor maternal care and neurochemical alterations, offspring sociability impairment (PubMed), Postpartum depression spans generations, animal study suggests (ScienceDaily)

Summary of Key Evidence Gaps for Curators

  1. No dedicated OMIM/Orphanet entry — PPD must be curated as a complex/multifactorial MONDO:0005929 entry, not linked to a Mendelian OMIM phenotype MIM number.
  2. GWAS loci did not reach genome-wide significance in the largest 2023 meta-analysis (lead TXNRD2 signal was suggestive, not GWS) — curate genetic evidence with appropriately hedged supports: PARTIAL classifications rather than definitive causal gene claims.
  3. Epigenetic biomarkers (HP1BP3/TTC9B) are prediction-stage research tools, not validated clinical diagnostics — do not conflate with an established diagnostic test.
  4. Brexanolone's FDA approval was withdrawn in April 2025 — any treatment entry must reflect current regulatory status (zuranolone remains the sole current FDA-approved PPD-specific pharmacotherapy) rather than presenting brexanolone as an actively marketed product.
  5. International screening-guideline divergence (US universal-EPDS-screening consensus vs. UK NICE's non-universal approach) is a genuine unresolved policy tension worth flagging as a discussion, not smoothing over as consensus.
  6. No documented naturally-occurring veterinary/OMIA analog was found — Section 14 content should be marked as a knowledge gap rather than populated with fabricated cross-species claims.
  7. Several statistics here (recurrence-risk percentage, exact maternal-suicide contribution figures) are cited as commonly-used clinical estimates from secondary sources; before final KB curation, each should be traced to and quote-verified against its specific primary PMID per the dismech evidence SOP.